Compounds > aspirin
Page last updated: 2024-10-23

aspirin and Diabetes Mellitus

aspirin has been researched along with Diabetes Mellitus in 451 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.

Research Excerpts

ExcerptRelevanceReference
"Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin."9.51Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022)
"Aspirin does not have a large proportional effect on the risk of dementia."9.51Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022)
"We sought to compare the biological efficacy of aspirin given once a day versus aspirin divided twice per day in a population of diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS) as assessed by the thrombin generation test."9.41ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial. ( Addad, F; Baccouche, H; Bennour, E; Boussofara, A; Halima, AB; Kachboura, S; Kammoun, I; Kasbaoui, S; Laroussi, L; Marrakchi, S; Romdhane, NB; Triki, H; Zied, EH, 2021)
"Compared with ticagrelor plus aspirin, the effect of ticagrelor monotherapy in reducing the risk of clinically relevant bleeding without any increase in ischemic events was consistent among patients with or without DM undergoing PCI."9.34Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Oldroyd, KG; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Weisz, G; Witzenbichler, B; Ya-Ling, H, 2020)
"In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)."9.30Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019)
" Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear."9.27Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018)
"There is a lack of evidence for pre-eclampsia prophylaxis with aspirin in women with pre-existing diabetes mellitus (DM)."9.22Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: Systematic review. ( Alahakoon, TI; Cheung, NW; Haider, R; Jesudason, S; Lee, VW; Nolan, CJ; Padmanabhan, S; Peek, M; Simmons, D; Zen, M, 2022)
"The role of aspirin in primary prevention of cardiovascular diseases (CVD) has been extensively evaluated; however, the results provided over the years have been controversial."9.22Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence. ( Dimitriadis, K; Lazarou, E; Soulaidopoulos, S; Tsioufis, K; Tsioufis, P, 2022)
"A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin."9.22Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016)
"The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients."9.19The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014)
"Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia."9.15Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011)
"The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients."9.14Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. ( Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."9.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI)."9.12Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo ( Wang, Q; Yang, K, 2021)
"The Early Treatment Diabetic Retinopathy Study (ETDRS), conducted at 22 clinical centers during the period 1980 to 1989, collected baseline data on C-peptide levels after ingestion of Sustacal in 582 patients with diabetes mellitus, prior to enrollment in the trial."9.07C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. ( Ewart, R; Kumar, D; Miller, D; Prior, MJ; Prout, T, 1993)
"This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)."9.07Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. ( , 1992)
"To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly."9.05Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020)
"The safety and efficacy of aspirin for the primary prevention of cardiovascular disease in patients with diabetes mellitus remains controversial."9.05Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. ( Ali, F; Kaluski, E; Khan, MU; Khan, SU; Krasuski, RA; Lone, AN; Mookadam, F; Shahzeb Khan, M; Talluri, S; Ul Abideen Asad, Z, 2020)
"The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk."9.01Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019)
"The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM)."8.85Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. ( Soran, H; Williams, S; Younis, N, 2009)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."8.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"The alterations in the metabolism of arachidonic acid to prostaglandin I2 (prostacyclin), a vasodilator antiaggregatory substance, and thromboxane A2, a vasoconstrictor proaggregatory substance, in diabetes mellitus are reviewed in this article."8.77Insulin and arachidonic acid metabolism in diabetes mellitus. ( Colwell, JA; Halushka, PV; Mayfield, R, 1985)
"This study aimed to evaluate whether there is an association between the US Preventive Services Taskforce aspirin guideline hypertensive disorders of pregnancy and the rates of hypertensive disorders of pregnancy and preterm birth in individuals with pregestational diabetes mellitus."8.31Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023)
"To investigate the association between low-dose aspirin use for primary prevention and self-reported kidney stones prevalence in the 40-79 years old population."8.31Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study. ( Chen, Y; Huang, F; Li, Y; Yang, M, 2023)
"Current guidelines recommend low-dose aspirin for preeclampsia prophylaxis in all women with pregestational (type one and type two) diabetes mellitus."8.12Associations between aspirin prophylaxis and fetal growth and preeclampsia in women with pregestational diabetes. ( Graham, DF; Shrestha Khatri, N; White, SW, 2022)
"Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins."8.12Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022)
"Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk."8.02Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021)
"Aspirin is routinely prescribed in high-risk pregnancies to prevent pre-eclampsia; however, there is a paucity of data in women with pre-existing diabetes."8.02Aspirin and pre-eclampsia prevention in women with pre-existing diabetes: a retrospective study. ( Athayde, N; Cheung, NW; Inglis, E; Lah, S; Lee, V; Padmanabhan, S, 2021)
"Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear."7.91Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2019)
"High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes."7.91Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019)
"Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes."7.85Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. ( Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017)
"Seventy patients with stable coronary artery disease, supplemented with aspirin, participated in this pilot study."7.85MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. ( Bil-Lula, I; Gąsior, M; Kaczmarski, J; Kuliczkowski, W; Mysiak, A; Negrusz-Kawecka, M; Radomski, M; Urbaniak, J, 2017)
"The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events."7.85Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. ( Eckman, MH; So, CH, 2017)
" Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel."7.83Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016)
"To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia."7.83Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016)
"To evaluate whether aspirin can reduce the risk of colorectal cancer in people with diabetes."7.81Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. ( Lai, MS; Lin, CC; Shau, WY, 2015)
"The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage."7.81Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015)
"Use of warfarin, low GCS score, opening to ventricle, older age, accompanying diabetes, and/or hypertension were worse prognostic factors."7.80Intracranial hemorrhages related with warfarin use and comparison of warfarin and acetylsalicylic acid. ( Beckmann, Y; Ciftçi, Y; Seçil, Y; Tokuçoğlu, F, 2014)
"Long-term administration of low-dose aspirin (LDA) is associated with a greater risk of adverse events, including gastroduodenal ulcers."7.79Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers. ( Funaki, Y; Iida, A; Ito, Y; Kasugai, K; Kawamura, N; Mizuno, M; Ogasawara, N; Sasaki, M, 2013)
"The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects."7.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"Exploration of atherogenic diet-induced diabetes mellitus and the evaluation of antidiabetic potential of aspirin were carried out in this study."7.77The effect of aspirin on atherogenic diet-induced diabetes mellitus. ( Kumar, A; Parmar, HS; Sethi, A, 2011)
"There have been no randomized trials of cardioprotective therapy after acute myocardial infarction in patients with chronic kidney disease who should be largely eligible for aspirin (acetylsalicylic acid; ASA) and beta-blockers (BB) as a base of therapy."7.71Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. ( Borzak, S; Garg, M; Hudson, MP; Manley, HJ; McCullough, PA; Sandberg, KR, 2002)
"The results of two large independent studies involving a combined total of 776 patients treated in hospital with a discharge diagnosis of acute myocardial infarction and 13,898 patients with other discharge diagnoses showed a negative association between regular aspirin intake and non-fatal myocardial infarction."7.65Regular aspirin intake and acute myocardial infarction. ( , 1974)
" However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation."6.79Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014)
"Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding."6.76Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. ( Angiolillo, DJ; Bass, TA; Box, LC; Capodanno, D; Capranzano, P; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Sumner, S; Ueno, M; Zenni, M, 2011)
"In this prospective, open-label, multi-centre, 2 × 2 factorial, randomized, controlled study, 1,800 patients with diabetes mellitus and multi-vessel disease (inclusion criteria similar to FREEDOM trial) with indication for coronary revascularization will be randomly assigned to Supraflex Cruz or Xience stents and also to ticagrelor- or prasugrel- based antiplatelet strategies."5.69Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2. ( Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK, 2023)
"Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin."5.51Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022)
"Aspirin does not have a large proportional effect on the risk of dementia."5.51Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022)
"Diabetes mellitus has been associated with a substantially increased risk of both first and recurrent atherothrombotic events, which makes aspirin therapy of potential value in these subjects."5.43Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. ( Angiolillo, DJ; Capodanno, D, 2016)
"Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent."5.41Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Cheema, AN; Eckstein, J; Lam, A; Liu, S, 2023)
"We sought to compare the biological efficacy of aspirin given once a day versus aspirin divided twice per day in a population of diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS) as assessed by the thrombin generation test."5.41ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial. ( Addad, F; Baccouche, H; Bennour, E; Boussofara, A; Halima, AB; Kachboura, S; Kammoun, I; Kasbaoui, S; Laroussi, L; Marrakchi, S; Romdhane, NB; Triki, H; Zied, EH, 2021)
"5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD)."5.41Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. ( Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Félix, C; Fox, KAA; Guzik, TJ; Hart, RG; Maggioni, AP; Muehlhofer, E; Sharma, M; Shestakovska, O; Yusuf, S, 2021)
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."5.39Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)
"5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events."5.34Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. ( Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Lewis, BS; Maggioni, AP; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Szarek, M; Verma, S; Widimský, P; Yusuf, S, 2020)
"Compared with ticagrelor plus aspirin, the effect of ticagrelor monotherapy in reducing the risk of clinically relevant bleeding without any increase in ischemic events was consistent among patients with or without DM undergoing PCI."5.34Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Oldroyd, KG; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Weisz, G; Witzenbichler, B; Ya-Ling, H, 2020)
"Aspirin non-response was defined as: 1) slope steeper than 12%/min in AA-aggregations, and 2) by closure time shorter than 170 s in PFA-100."5.33Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. ( Backman, JT; Kankuri, E; Karhunen, PJ; Lassila, R; Lepäntalo, A; Mikkelsson, J; Reséndiz, JC; Viiri, L, 2006)
"In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)."5.30Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019)
" Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear."5.27Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018)
" One-step extraction of UTXB2 with an octadecylsilyl-silica column was sufficient as pretreatment for TXB2 radioimmunoassay because recovery of UTXB2 was good, the eluate was parallel with the dose-response curve, and the value coincided with that obtained by the conventional method."5.27Increased thromboxane B2 excretion in diabetes mellitus. ( Inaba, M; Ishii, J; Katayama, S; Kawazu, S; Maruno, Y; Omoto, A, 1987)
" In the uncommon occurrence of asthma and diabetes in the same patient, insulin dosage should be considered as a factor in all such asthmatics who do not respond well to conventional therapy."5.26Diabetes mellitus and insulin in an aspirin sensitive asthmatic. ( Caplin, I, 1976)
"There is a lack of evidence for pre-eclampsia prophylaxis with aspirin in women with pre-existing diabetes mellitus (DM)."5.22Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: Systematic review. ( Alahakoon, TI; Cheung, NW; Haider, R; Jesudason, S; Lee, VW; Nolan, CJ; Padmanabhan, S; Peek, M; Simmons, D; Zen, M, 2022)
"The role of aspirin in primary prevention of cardiovascular diseases (CVD) has been extensively evaluated; however, the results provided over the years have been controversial."5.22Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence. ( Dimitriadis, K; Lazarou, E; Soulaidopoulos, S; Tsioufis, K; Tsioufis, P, 2022)
" The prediction rule assigned 1 point each for myocardial infarction at presentation, prior myocardial infarction or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein graft intervention; -1 point for age 65 to younger than 75 years; and -2 points for age 75 years or older."5.22Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. ( Apruzzese, PK; Camenzind, E; Cohen, DJ; Cutlip, DE; Gershlick, AH; Kereiakes, DJ; Massaro, JM; Mauri, L; Normand, SL; Rinaldi, MJ; Secemsky, EA; Song, Y; Spertus, JA; Steg, PG; Wijns, W; Yeh, RW, 2016)
"A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin."5.22Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016)
"The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients."5.19The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014)
"Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors."5.19Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2014)
"Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia."5.15Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011)
"The Japanese Primary Prevention Project (JPPP) is a multicenter, open-label, randomized, parallel-group trial that is evaluating primary prevention with low-dose aspirin in Japanese patients aged 60 to 85 years with hypertension, dyslipidemia, or diabetes mellitus."5.14Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamada, N; Yamazaki, T; Yokoyama, K, 2010)
"The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients."5.14Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. ( Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."5.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI)."5.12Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo ( Wang, Q; Yang, K, 2021)
"0001) after adjustment for age, aspirin use, smoking, physical activity, body mass index, and history of angina, hypertension, and high cholesterol."5.09Alcohol consumption and risk of coronary heart disease by diabetes status. ( Ajani, UA; Buring, JE; Gaziano, JM; Hennekens, CH; Liu, S; Lotufo, PA; Manson, JE, 2000)
"The Early Treatment Diabetic Retinopathy Study (ETDRS), conducted at 22 clinical centers during the period 1980 to 1989, collected baseline data on C-peptide levels after ingestion of Sustacal in 582 patients with diabetes mellitus, prior to enrollment in the trial."5.07C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. ( Ewart, R; Kumar, D; Miller, D; Prior, MJ; Prout, T, 1993)
"This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)."5.07Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. ( , 1992)
"To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly."5.05Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020)
"The safety and efficacy of aspirin for the primary prevention of cardiovascular disease in patients with diabetes mellitus remains controversial."5.05Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. ( Ali, F; Kaluski, E; Khan, MU; Khan, SU; Krasuski, RA; Lone, AN; Mookadam, F; Shahzeb Khan, M; Talluri, S; Ul Abideen Asad, Z, 2020)
"The blocking effects of aspirin, chlorpheniramine, and cimetidine were tested against the flush provoked by alcohol in twenty-four chlorpropamide-treated patients with non-insulin-dependent diabetes mellitus."5.05Blockade of chlorpropamide alcohol flush by aspirin. ( Jefferys, DB; Keen, H; Strakosch, CR, 1980)
"The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk."5.01Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019)
"Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer."4.95Aspirin for Primary Prevention. ( Owens, DK; Richman, IB, 2017)
"A literature search was conducted using the terms cardiovascular disease, aspirin, diabetes mellitus to identify trials of patients with diabetes who received aspirin for primary prevention of CVD."4.93Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis. ( Berlie, HD; Garwood, CL; Kokoska, LA; Wilhelm, SM, 2016)
"Clinical trials investigating the role of aspirin in primary prevention have led to an adjustment in the indication for aspirin in metabolic syndrome patients at intermediate risk of a cardiovascular event."4.86A practical approach to the metabolic syndrome: review of current concepts and management. ( Blaha, MJ; Blumenthal, RS; Defilippis, AP; Tota-Maharaj, R, 2010)
"The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM)."4.85Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. ( Soran, H; Williams, S; Younis, N, 2009)
" We used the search terms metabolic syndrome, abdominal obesity, waist circumference, insulin resistance, cardiovascular disease, prediabetes, diabetes, treatment, prevention, aspirin, hypertension, cholesterol, atherogenic dyslipidemia, lifestyle therapy, diet, and exercise."4.84A practical "ABCDE" approach to the metabolic syndrome. ( Bansal, S; Blaha, MJ; Blumenthal, RS; Defilippis, AP; Golden, SH; Rouf, R, 2008)
"Aspirin is recommended as cardiovascular disease prevention in patients with diabetes mellitus."4.84[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications]. ( Camargo, EG; Gross, JL; Lavinsky, J; Silveiro, SP; Weinert, LS, 2007)
" Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity."4.83Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."4.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
" Aspirin is one of the most prescribed treatments in the prevention of cardiovascular diseases."4.82[Should we treat all diabetic patients with aspirin in primary prevention?]. ( De Moerloose, P; Philippe, J; Righetti, A, 2005)
"The alterations in the metabolism of arachidonic acid to prostaglandin I2 (prostacyclin), a vasodilator antiaggregatory substance, and thromboxane A2, a vasoconstrictor proaggregatory substance, in diabetes mellitus are reviewed in this article."4.77Insulin and arachidonic acid metabolism in diabetes mellitus. ( Colwell, JA; Halushka, PV; Mayfield, R, 1985)
"This study aimed to evaluate whether there is an association between the US Preventive Services Taskforce aspirin guideline hypertensive disorders of pregnancy and the rates of hypertensive disorders of pregnancy and preterm birth in individuals with pregestational diabetes mellitus."4.31Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023)
"To investigate the association between low-dose aspirin use for primary prevention and self-reported kidney stones prevalence in the 40-79 years old population."4.31Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study. ( Chen, Y; Huang, F; Li, Y; Yang, M, 2023)
"Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score."4.12Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022)
"Current guidelines recommend low-dose aspirin for preeclampsia prophylaxis in all women with pregestational (type one and type two) diabetes mellitus."4.12Associations between aspirin prophylaxis and fetal growth and preeclampsia in women with pregestational diabetes. ( Graham, DF; Shrestha Khatri, N; White, SW, 2022)
"Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins."4.12Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022)
"Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk."4.02Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021)
"Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases."4.02The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. ( Avramovich, E; Frenkel-Morgenstern, M; Golan-Cohen, A; Gorohovski, A; Green, I; Magen, E; Merzon, E; Vinker, S, 2021)
"Aspirin is routinely prescribed in high-risk pregnancies to prevent pre-eclampsia; however, there is a paucity of data in women with pre-existing diabetes."4.02Aspirin and pre-eclampsia prevention in women with pre-existing diabetes: a retrospective study. ( Athayde, N; Cheung, NW; Inglis, E; Lah, S; Lee, V; Padmanabhan, S, 2021)
"The present study concluded that long-term dual antiplatelet therapy including clopidogrel and aspirin could decrease the risks of all-cause death, myocardial infarction."4.02Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. ( Guo, L; Man, F; Pan, Q; Wang, W; Wang, X; Zhang, J; Zhang, L, 2021)
"This study aimed to determine the effect of preoperative aspirin administration on early and long-term clinical outcomes in patients suffering from diabetes mellitus (DM) undergoing coronary artery bypass grafting (CABG)."3.96Impact of Preoperative Aspirin on Long-Term Outcomes in Diabetic Patients Following Coronary Artery Bypass Grafting: a Propensity Score Matched Study. ( Aboul-Hassan, SS; Cichon, R; Lipowski, A; Marczak, J; Moskal, L; Nawotka, M; Peksa, M; Sá, MPBO; Stanislawski, R; Stankowski, T, 2020)
"Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear."3.91Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2019)
"We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project."3.91Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019)
" In diabetic patients treated with DAPT (ASA + clopidogrel or ticagrelor) platelet reactivity was assessed at 30-90 days post-discharge for an acute coronary syndrome or elective PCI."3.91Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. ( Carriero, A; De Luca, G; Kedhi, E; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Tonon, F; Verdoia, M, 2019)
"High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes."3.91Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019)
"Among diabetic patients receiving dual antiplatelet therapy for an acute coronary syndrome or elective percutaneous coronary intervention, severe vitamin D deficiency is associated with a higher ADP-mediated platelet reactivity and rate of HRPR, and especially for new ADP-antagonists over clopidogrel."3.91Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. ( Carriero, A; De Luca, G; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M, 2019)
" Recommendations address diagnosis and treatment of cardiovascular risk factors (hypertension and dyslipidemia), aspirin use, screening for and treatment of coronary heart disease, and lifestyle interventions."3.88Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. ( Chamberlain, JJ; Johnson, EL; Leal, S; Peterson, L; Rhinehart, AS; Shubrook, JH, 2018)
"Our findings suggest that a cumulative aspirin dosage of more than 88,900 mg daily was associated with a reduced risk of breast cancer in women with diabetes."3.85Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan. ( Chiou, JY; Huang, CN; Kornelius, E; Lai, YR; Lo, SC; Peng, CH; Yang, YS, 2017)
"Seventy patients with stable coronary artery disease, supplemented with aspirin, participated in this pilot study."3.85MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. ( Bil-Lula, I; Gąsior, M; Kaczmarski, J; Kuliczkowski, W; Mysiak, A; Negrusz-Kawecka, M; Radomski, M; Urbaniak, J, 2017)
" In a cross-sectional study of 787 patients with newly diagnosed clinical stage IB or II melanoma, we estimated odds ratios for the association of proinflammatory factors (high body mass index, diabetes, cardiovascular disease, hypertension, and smoking) or the use of anti-inflammatory medications (statins, aspirin, corticosteroids, and nonsteroidal anti-inflammatory drugs), with ulcerated primary melanoma using regression models and subgroup analyses to control for melanoma thickness and mitotic rate."3.85Associations of Statins and Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma. ( Green, AC; Hughes, MCB; Khosrotehrani, K; Malt, M; Smith, D; Smithers, BM; van der Pols, JC; von Schuckmann, LA, 2017)
"The combined use of aspirin and oral anticoagulant therapy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) has been questioned due to an increased risk of major bleeding with little to no benefit in preventing ischemic events."3.85Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. ( Eckman, MH; So, CH, 2017)
" Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel."3.83Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016)
" In patients treated with ASA (100-160 mg) and clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) platelet reactivity and the reticulated platelets fraction (immature platelets fraction, IPF) were assessed at 30-90 days post-discharge for an acute coronary syndrome or elective PCI."3.83Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016)
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)."3.83Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016)
"To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia."3.83Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016)
"To evaluate whether aspirin can reduce the risk of colorectal cancer in people with diabetes."3.81Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. ( Lai, MS; Lin, CC; Shau, WY, 2015)
"Low-dose aspirin has been hypothesized as being a potential host modulatory agent for periodontitis treatment."3.81Association between low-dose aspirin and periodontal disease: results from the continuous national health and nutrition examination survey (NHANES) 2011-2012. ( Demmer, RT; Ioannou, AL; Kotsakis, GA; Michalowicz, BS; Thai, A, 2015)
"The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage."3.81Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015)
"Use of warfarin, low GCS score, opening to ventricle, older age, accompanying diabetes, and/or hypertension were worse prognostic factors."3.80Intracranial hemorrhages related with warfarin use and comparison of warfarin and acetylsalicylic acid. ( Beckmann, Y; Ciftçi, Y; Seçil, Y; Tokuçoğlu, F, 2014)
" In addition, patients in the 6 am to 2 pm subgroup were more likely older, white race, and male, with higher rates of home aspirin use and lower rates of obesity."3.79Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. ( Antman, EM; Cannon, CP; Foody, JM; Giugliano, RP; Li, S; Mogabgab, O; Sabatine, MS; Wang, TY; Wiviott, SD, 2013)
"Long-term administration of low-dose aspirin (LDA) is associated with a greater risk of adverse events, including gastroduodenal ulcers."3.79Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers. ( Funaki, Y; Iida, A; Ito, Y; Kasugai, K; Kawamura, N; Mizuno, M; Ogasawara, N; Sasaki, M, 2013)
"Diabetes mellitus (DM) is associated with increased platelet activation and reduced platelet inhibition by clopidogrel."3.79Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. ( Desta, Z; Flockhart, DA; Jin, Y; Kovacs, R; Kreutz, RP; Kreutz, Y; Miao, J; Nystrom, P, 2013)
"The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects."3.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"The proper use of statins and aspirin decrease the risk of coronary heart disease (CHD) among patients with diabetes (DM) and hyperlipidemia."3.78Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006. ( Chen, YJ; Hwu, CM; Li, CY; Lin, YC; Peng, WC; Yang, CC, 2012)
"Exploration of atherogenic diet-induced diabetes mellitus and the evaluation of antidiabetic potential of aspirin were carried out in this study."3.77The effect of aspirin on atherogenic diet-induced diabetes mellitus. ( Kumar, A; Parmar, HS; Sethi, A, 2011)
"We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy."3.76Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010)
"Treatment with aspirin is underused for PP in patients with diabetes mellitus in Primary Care."3.74Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. ( Fernández-de-Bobadilla, J; Frías-Garrido, X; Navarro-Artieda, R; Rejas-Gutiérrez, J; Ruiz-Riera, R; Sicras-Mainar, A, 2007)
"There have been no randomized trials of cardioprotective therapy after acute myocardial infarction in patients with chronic kidney disease who should be largely eligible for aspirin (acetylsalicylic acid; ASA) and beta-blockers (BB) as a base of therapy."3.71Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. ( Borzak, S; Garg, M; Hudson, MP; Manley, HJ; McCullough, PA; Sandberg, KR, 2002)
"Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke."3.70Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000)
"(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age."3.70Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000)
"The results of two large independent studies involving a combined total of 776 patients treated in hospital with a discharge diagnosis of acute myocardial infarction and 13,898 patients with other discharge diagnoses showed a negative association between regular aspirin intake and non-fatal myocardial infarction."3.65Regular aspirin intake and acute myocardial infarction. ( , 1974)
"Proteinuria was independently associated with the incidence of primary cardiovascular events in diabetic patients."2.94Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients. ( Jinnouchi, H; Masuda, I; Matsumoto, C; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Waki, M, 2020)
"Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup."2.90Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019)
"The protective effect of statin against gastric cancer was also significant in patients with diabetes mellitus."2.82Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. ( Bang, CS; Kim, HH; Kim, J; Kim, JY; Kim, TJ; Lee, KJ; Park, CH; Seo, SI; Shin, WG; You, SC, 2022)
" Previous pharmacokinetic and pharmacodynamic studies have suggested that the aspirin formulation (enteric-coated) and dosing schedule (once daily) studied in randomized trials for primary prevention of CV events defining contemporary clinical practice may not leverage the full potential of the drug, particularly in patients with diabetes."2.82Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. ( Bloom, S; Del Bianco-Rondeau, M; Lordkipanidzé, M; Marquis-Gravel, G; Rabasa-Lhoret, R; Robert-Halabi, M; Tardif, JC, 2022)
" However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation."2.79Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014)
"Cilostazol is a platelet inhibitor which when added to aspirin and clopidogrel has shown to reduce the risk of recurrent ischaemic events without an increase in bleeding."2.76Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. ( Angiolillo, DJ; Bass, TA; Box, LC; Capodanno, D; Capranzano, P; Charlton, RK; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Guzman, LA; Sumner, S; Ueno, M; Zenni, M, 2011)
"Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed."2.69Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999)
"Observational data from the Early Treatment Diabetic Retinopathy Study."2.68Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. ( Chantry, K; Chew, EY; Ferris, FL; Hoogwerf, BJ; Klein, ML; Miller, D; Murphy, RP; Remaley, NA, 1996)
" Further dosage adjustments are made in accordance with a set protocol."2.67The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. ( Hansson, L; Zanchetti, A, 1994)
"Aspirin has potential benefits in cardiovascular primary prevention in diabetes."2.61Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. ( Buring, JE; Gaziano, JM; Khunti, K; Kunutsor, SK; Roncaglioni, MC; Seidu, S; Sesso, HD, 2019)
"Aspirin was associated with reductions in major cardiovascular events (risk ratio, 0."2.50Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. ( Bao, W; Chen, S; Hu, FB; Liu, L; Rong, Y; Shan, Z; Xie, M; Yang, W; Yu, X; Zhang, Y, 2014)
"Aspirin use was associated with a significantly lower risk of mortality (RR: 0."2.47Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. ( Chambers, T; Gamble, JM; Mereu, L; Simpson, SH, 2011)
"Diabetes mellitus is commonly associated with both microvascular and macrovascular complications (coronary artery disease, cerebrovascular events, severe peripheral vascular disease, nephropathy and retinopathy)."2.45Diabetes, vascular complications and antiplatelet therapy: open problems. ( Cerbone, AM; Coppola, A; Di Minno, G; Macarone-Palmieri, N; Rivellese, AA; Saldalamacchia, G, 2009)
"Diabetes mellitus is a well-recognized risk-factor for coronary artery disease."2.43[Coronary heart disease in patients with diabetes mellitus]. ( Nakayama, M; Ogawa, H, 2006)
"Management of hypertension in diabetic nephropathy is challenging and generally requires a minimum of three different and complementary antihypertensive agents to achieve the recently recommended blood pressure (BP) goal of <130/80 mm Hg in order to reduce cardiovascular (CV) risk and preserve kidney function."2.42Diabetes and chronic kidney disease: tragedy and challenge. ( Bakris, GL; Chua, DY, 2004)
"Diabetes mellitus is another CHD risk factor which is stronger in women than in men, and CHD death rates are 3-7 times greater among diabetic than nondiabetic women."2.40Risk factors for coronary heart disease in women. ( Hennekens, CH, 1998)
"Aspirin treatment again has similar benefits to those in non-diabetic subjects, and should be administered at presentation."2.40Managing the diabetic patient with acute myocardial infarction. ( Yudkin, JS, 1998)
"001) in a dose-response fashion, and these associations were prominent among participants with a metformin cumulative defined daily dose of 547."1.62The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. ( Cho, JH; Cho, M; Jeong, SM; Kang, J; Kim, J; Shin, DW, 2021)
"Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug has to alter the effects of another when both are administered simultaneously."1.56Potential drug-drug interactions in ICU patients: a retrospective study. ( Ali, I; Bazzar, A; Hussein, N; Sahhar, E, 2020)
"Aspirin is an effective, low cost option to reduce cardiovascular events."1.51Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs. ( Duval, S; Eder, M; Jones, C; Luepker, RV; Misialek, JR; Oldenburg, NC; Van't Hof, JR, 2019)
"The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present."1.43Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. ( Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016)
"Diabetes mellitus has been associated with a substantially increased risk of both first and recurrent atherothrombotic events, which makes aspirin therapy of potential value in these subjects."1.43Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. ( Angiolillo, DJ; Capodanno, D, 2016)
"Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation."1.39Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013)
"Medical records of 659 patients treated for myocardial infarction at the 1st Department of Internal Medicine-Cardiology of Borsod-Abaúj-Zemplén County Hospital and University Hospital were analyzed."1.39Pharmaceutical care for patients with acute myocardial infarction in Hungary. ( Argay, M; Dormaeva, I; Hankó, B; Koós, I; Meskó, A; Takács, I; Zelkó, R, 2013)
"Diabetes mellitus is associated with platelet hyperactivity, which leads to increased morbidity and mortality from cardiovascular disease."1.37Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. ( Capone, M; Di Febbo, C; Evangelista, V; Fava, C; Gleim, S; Hwa, J; Levantesi, G; Martin, K; Minuz, P; Patrignani, P; Porreca, E; Rade, J; Stitham, J; Tacconelli, S; Tang, WH; Wen, L, 2011)
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."1.36Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"Aspirin use was reported in 50% of patients: 68."1.36Aspirin use in elderly women receiving medication therapy management services. ( Cooke, CE; Lee, HY; Tong, YP; Xing, S, 2010)
"Age and left bundle branch block were strong negative predictors for early reperfusion therapy in patients with prior antithrombotic treatment."1.35Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Koeth, O; Senges, J; Towae, F; Zahn, R; Zeymer, U, 2009)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."1.34Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
"Aspirin use was significantly lower among the study participants (23%) compared to the reported national prevalence of aspirin intake (64%)."1.34Health issues in the Arab American community. The use of glucose-lowering agents and aspirin among Arab Americans with diabetes. ( Berlie, HD; Hammad, A; Jaber, LA, 2007)
"The progress of leukoaraiosis is greatly inhibited by long-term correction of platelet hyper-aggregability."1.33Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. ( Fujita, S; Fukushima, K; Kawaguchi, T; Uehara, T, 2005)
"Aspirin non-response was defined as: 1) slope steeper than 12%/min in AA-aggregations, and 2) by closure time shorter than 170 s in PFA-100."1.33Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. ( Backman, JT; Kankuri, E; Karhunen, PJ; Lassila, R; Lepäntalo, A; Mikkelsson, J; Reséndiz, JC; Viiri, L, 2006)
"Diabetes mellitus is a major public health problem in the United States."1.33Increased cardiovascular risk associated with diabetes in Dallas County. ( Das, SR; de Lemos, JA; Dobbins, RL; McGuire, DK; Stanek, HG; Vaeth, PA, 2006)
"People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thrombo-vascular complications than non-diabetics and it is recommended that they should use acetylsalicylic acid (ASA) as anitiplatelet agent regularly."1.33Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus. ( Drzewoski, J; Liniarski, M; Olszewski, A; Sawer-Szewczyk, J; Stepień, A, 2005)
"Diabetes Mellitus is a chronic disease frequently associated to ischemic heart disease and both disease require continuing medical care, aggressive treatment of other risk factors, educational programs for self management of disease to prevent acute complication."1.32[Recommendations for cardiovascular rehabilitation in diabetes mellitus]. ( Biorci, ML; Camerini, A; Chieffo, C; Comaschi, M; Faglia, E; Fattirolli, F; Gattone, M; Giorda, C; Griffo, R; Mannucci, E, 2003)
" A dose-response relationship was evident between incident opacities and increased levels of glycosylated hemoglobin at baseline, with the highest risk of cortical (RR = 3."1.32Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. ( Hennis, A; Leske, MC; Nemesure, B; Wu, SY, 2004)
"Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB."1.31Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. ( de Andres, R; Farré, J; García-Méndez, A; Gómez, J; López-Farré, A; Mateos-Cáreres, PJ; Rico, L; Romero, J; Sánchez de Miguel, L, 2002)
"Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4."1.31Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001)
"The value of treatment of hyperlipidemia in reducing the incidence of a first stroke remains to be demonstrated."1.28Ischemic stroke. How to keep the first one from happening. ( Bundlie, SR, 1991)
"Patients with transient ischemic attacks (TIA) were previously shown to have high plasma values of thiobarbituric acid-reactive substances (TBA-RS)."1.28Blood lipid peroxides in TIA: relation to platelet function and metabolic profile. ( Alessandri, C; Balsano, F; Caliendo, C; Censi, C; Germani, M; Ghiselli, A; Servi, M; Violi, F, 1989)
" One-step extraction of UTXB2 with an octadecylsilyl-silica column was sufficient as pretreatment for TXB2 radioimmunoassay because recovery of UTXB2 was good, the eluate was parallel with the dose-response curve, and the value coincided with that obtained by the conventional method."1.27Increased thromboxane B2 excretion in diabetes mellitus. ( Inaba, M; Ishii, J; Katayama, S; Kawazu, S; Maruno, Y; Omoto, A, 1987)
"Human diabetes mellitus is characterized by impaired insulin response to intravenous glucose."1.26Impaired insulin secretion in human diabetes mellitus. II. A possible role for prostaglandins. ( Coppola, L; Giugliano, D; Misso, L; Sgamboto, S; Torella, R, 1981)
" Nine of 14 diabetics received a dosage of 1."1.26Effect of acetylsalicylic acid on blood glucose and glucose regulatory hormones in mild diabetes. ( Ikeda, M; Imura, H; Ishida, H; Nakahara, H; Nishi, S; Seino, Y; Takemura, J; Usami, M, 1982)
"Diclofenac (Voltarol) has no effect on carbohydrate metabolism, insulin levels or tolbutamide metabolism, nor does it enhance the effect of tolbutamide, biguanide or glibenclamide."1.26Diclofenac sodium (Voltarol): drug interactions and special studies. ( Fowler, PD, 1979)
" In the uncommon occurrence of asthma and diabetes in the same patient, insulin dosage should be considered as a factor in all such asthmatics who do not respond well to conventional therapy."1.26Diabetes mellitus and insulin in an aspirin sensitive asthmatic. ( Caplin, I, 1976)

Research

Studies (451)

TimeframeStudies, this research(%)All Research%
pre-199089 (19.73)18.7374
1990's31 (6.87)18.2507
2000's110 (24.39)29.6817
2010's144 (31.93)24.3611
2020's77 (17.07)2.80

Authors

AuthorsStudies
Zhang, HB1
Zhang, YA1
Wu, GZ1
Zhou, JP1
Huang, WL1
Hu, XW1
Kow, CS1
Ramachandram, DS1
Hasan, SS1
Altınay, L1
Çetin, E1
Tantry, US1
Gurbel, PA1
Dai, L1
Xu, J1
Yan, H1
Chen, Z1
Pan, Y1
Meng, X1
Li, H2
Wang, Y1
Shrestha Khatri, N1
White, SW1
Graham, DF1
Zen, M1
Haider, R1
Simmons, D1
Peek, M1
Nolan, CJ1
Padmanabhan, S2
Jesudason, S1
Alahakoon, TI1
Cheung, NW2
Lee, VW1
Harper, C2
Mafham, M7
Herrington, W2
Staplin, N2
Stevens, W6
Wallendszus, K5
Haynes, R7
Landray, MJ2
Parish, S6
Bowman, L8
Armitage, J8
Seo, SI1
Park, CH1
Kim, TJ1
Bang, CS1
Kim, JY1
Lee, KJ1
Kim, J2
Kim, HH1
You, SC1
Shin, WG1
Masson, W1
Barbagelata, L1
Lavalle-Cobo, A1
Lobo, M1
Masson, G1
Nogueira, JP1
Vergès, B1
Del Bianco-Rondeau, M1
Robert-Halabi, M1
Bloom, S1
Rabasa-Lhoret, R1
Tardif, JC1
Lordkipanidzé, M1
Marquis-Gravel, G1
Cavallari, I3
Patti, G1
Maddaloni, E2
Veneziano, F2
Mangiacapra, F2
Ricottini, E2
Buzzetti, R1
Ussia, GP2
Grigioni, F2
Dehghani, P1
Cao, D1
Baber, U5
Nicolas, J1
Sartori, S4
Pivato, CA1
Zhang, Z1
Dangas, G4
Angiolillo, DJ12
Briguori, C2
Cohen, DJ6
Collier, T2
Dudek, D2
Gibson, M2
Gil, R1
Huber, K2
Kaul, U3
Kornowski, R2
Krucoff, MW3
Kunadian, V2
Mehta, S1
Moliterno, DJ3
Ohman, EM1
Escaned, J4
Sardella, G2
Sharma, SK1
Shlofmitz, R1
Weisz, G4
Witzenbichler, B4
Pocock, S4
Mehran, R5
Offer, A1
Barton, J4
Buck, G5
Collins, R5
Kristensen, SD2
Olesen, KKW3
Maeng, M4
Seng Bong Ing, N1
Amoud, R1
Gamble, JM2
Alsabbagh, MW1
Wang, M1
Yu, H1
Li, Z1
Gong, D1
Liu, X2
Mihaljevic, MZ1
Petricevic, M1
Konosic, S1
Svetina, L1
Urlic, M1
Starcevic, Z1
Krzelj, K1
Milosevic, M1
Kalamar, V1
Gasparovic, H1
Biocina, B1
Dimitriadis, K1
Lazarou, E1
Tsioufis, P1
Soulaidopoulos, S1
Tsioufis, K1
Tasdemiroglu, Y1
Gourdie, RG1
He, JQ1
Nobile, E1
De Filippis, A1
Galli, M1
Rollini, F2
Been, L1
Zenni, MM1
Franchi, F2
Park, IB3
Seo, HJ3
Dai, Y1
Xu, R1
Wu, G1
Yin, Z1
Zhang, H1
Chen, W1
Yang, YS2
Kornelius, E2
Lo, SC2
Wang, YH1
Huang, CN2
Caldeira, D2
Alves, M2
Ferreira, JJ2
Pinto, FJ2
Bruno, AM1
Allshouse, AA1
Metz, TD1
Theilen, LH1
Liu, S2
Eckstein, J1
Lam, A1
Cheema, AN1
Arambam, P1
Sinha, SK1
Abhaichand, R1
Parida, AK1
Banker, D1
Mody, R1
Khan, A1
Sharma, R2
Moorthy, N1
Chandra, S1
Koduganti, SC1
Garg, R1
Sarma, PR1
Agrawal, DK1
Reddy, KMK1
Bangalore, S2
Aung, T5
Clark, S1
Hill, MR1
Kristensen, AMD1
Pareek, M1
Kragholm, KH1
Torp-Pedersen, C1
McEvoy, JW1
Prescott, EB1
Rhee, TM1
Bae, JW1
Park, KW1
Rha, SW1
Kang, J2
Lee, H1
Yang, HM1
Kwak, SH1
Chae, IH2
Shin, WY1
Kim, DK1
Oh, JH1
Jeong, MH1
Kim, YH2
Lee, NH2
Hur, SH1
Yoon, J1
Han, JK1
Shin, ES1
Koo, BK1
Kim, HS3
Pugliese, NR1
Taddei, S1
Zhou, Z1
Curtis, AJ1
Owen, A1
Wolfe, R1
Murray, AM1
Tonkin, AM1
Ernst, ME1
Orchard, SG1
Zhu, C1
Carr, PR1
Reid, CM1
Espinoza, SE1
Shah, RC1
Woods, RL1
Ryan, J1
McNeil, JJ1
Nelson, MR1
Zoungas, S1
Verma, SK1
Kalra, S1
Chunawala, ZS1
Caughey, MC1
Bhatt, DL10
Hendrickson, M1
Arora, S1
Erwin, JP1
Levisay, JP1
Rosenberg, JR1
Ricciardi, MJ1
Blankstein, R1
Matsushita, K1
Smith, S1
Qamar, A1
Yang, M1
Li, Y3
Chen, Y1
Huang, F1
Schrör, K2
Storey, RF1
Verheugt, FWA1
Roshandel, G1
Khoshnia, M1
Poustchi, H1
Hemming, K1
Kamangar, F1
Gharavi, A1
Ostovaneh, MR1
Nateghi, A1
Majed, M1
Navabakhsh, B1
Merat, S1
Pourshams, A1
Nalini, M1
Malekzadeh, F1
Sadeghi, M1
Mohammadifard, N1
Sarrafzadegan, N1
Naemi-Tabiei, M1
Fazel, A1
Brennan, P1
Etemadi, A1
Boffetta, P1
Thomas, N1
Marshall, T1
Cheng, KK1
Malekzadeh, R1
Rosenberg, K1
Soejima, H1
Ogawa, H2
Morimoto, T1
Okada, S1
Matsumoto, C1
Nakayama, M2
Masuda, I1
Jinnouchi, H1
Waki, M1
Saito, Y1
Zheng, J1
Xie, SH1
Santoni, G1
Lagergren, J1
Grant, PJ1
Cosentino, F1
Bressi, E1
Colaiori, I1
Capuano, M1
Viscusi, MM1
Spoto, S1
Barbato, E1
Di Sciascio, G1
Mafham, MM1
Bowman, LJ1
Haynes, RJ1
Armitage, JM1
David, C1
Costa, J1
Steg, PG7
Hohnloser, SH1
Nordaby, M1
Miede, C1
Kimura, T1
Lip, GYH1
Oldgren, J1
Ten Berg, JM1
Cannon, CP4
Verdoia, M5
Pergolini, P5
Nardin, M5
Rolla, R5
Negro, F2
Gioscia, R1
Fierro, N1
Saghir Afifeh, AM1
Viglione, F1
Suryapranata, H5
De Luca, G5
Sagar, RC1
Naseem, KM1
Ajjan, RA2
Eikelboom, JW4
Connolly, SJ3
Anand, SS3
Verma, S1
Branch, KRH2
Probstfield, J1
Bosch, J2
Shestakovska, O2
Szarek, M1
Maggioni, AP2
Widimský, P1
Avezum, A3
Diaz, R1
Lewis, BS1
Berkowitz, SD3
Fox, KAA4
Ryden, L1
Yusuf, S4
Mehta, SR1
Gibson, CM2
Chandiramani, R1
Oldroyd, KG1
Ya-Ling, H1
Sharma, S1
Shlofmitz, RA1
Clemens, KK1
Woodward, M1
Neal, B1
Zinman, B1
Shufelt, CL1
Manson, JE2
Serruys, PW1
Takahashi, K1
Chichareon, P1
Onuma, Y1
Patel, NJ1
Baliga, RR1
Wu, B1
Shi, L1
Ali, I1
Bazzar, A1
Hussein, N1
Sahhar, E1
Colak, B1
Orhan, A1
Ece, I1
Yormaz, S1
Yilmaz, H1
Sahin, M1
Boussofara, A1
Laroussi, L1
Baccouche, H1
Bennour, E1
Kasbaoui, S1
Triki, H1
Zied, EH1
Kammoun, I1
Halima, AB1
Addad, F2
Marrakchi, S1
Romdhane, NB1
Kachboura, S1
Fras, Z1
Sahebkar, A1
Banach, M1
Kataruka, A1
Mahtta, D1
Akeroyd, JM1
Hira, RS1
Kazi, DS1
Spertus, JA3
Petersen, LA1
Ballantyne, CM1
Virani, SS1
Choudhary, R1
Deora, S1
Dangas, GD1
Jeong, SM1
Shin, DW1
Cho, M1
Cho, JH1
Kaplovitch, E1
Dyal, L1
Aboyans, V2
Abola, MT1
Verhamme, P1
Bangdiwala, SI1
Koi, M1
Okita, Y1
Takeda, K1
Koeppe, ES1
Stoffel, EM1
Galanko, JA1
McCoy, AN1
Keku, T1
Carethers, JM1
Carlin, CS1
Peterson, K1
Solberg, LI1
Ramondou, P1
Hersant, J1
Fouquet, O1
Sempore, WY1
Abraham, P1
Henni, S1
Wang, HY1
Cai, ZX1
Yin, D1
Yang, YJ1
Song, WH1
Dou, KF1
Aboul-Hassan, SS1
Stankowski, T1
Marczak, J1
Peksa, M1
Nawotka, M1
Stanislawski, R1
Moskal, L1
Lipowski, A1
Sá, MPBO1
Cichon, R1
Merzon, E1
Green, I1
Vinker, S1
Golan-Cohen, A1
Gorohovski, A1
Avramovich, E1
Frenkel-Morgenstern, M1
Magen, E1
Lah, S1
Lee, V1
Athayde, N1
Inglis, E1
Clarkson, SA1
Heindl, B1
Cai, A1
Beasley, M1
Dillon, C1
Limdi, N1
Brown, TM1
Wang, Q1
Yang, K1
Haji Aghajani, M1
Moradi, O1
Amini, H1
Azhdari Tehrani, H1
Pourheidar, E1
Rabiei, MM1
Sistanizad, M1
Dillinger, JG1
Henry, P1
Heide-Jørgensen, U1
Thim, T2
Thomsen, RW1
Bøtker, HE2
Sørensen, HT2
Hatakeyama, Y1
Horino, T1
Matsumoto, T1
Terada, Y1
Okuhara, Y1
Trejo-Velasco, B1
Tello-Montoliu, A2
Cruz-González, I1
Moreno, R3
Baz-Alonso, JA1
Salvadores, PJ1
Romaguera, R1
Molina-Navarro, E1
Paredes-Galán, E1
Fernández-Barbeira, S1
Ortiz-Saez, A1
Bastos-Fernandez, G1
De Miguel-Castro, A1
Figueiras-Guzman, A1
Iñiguez-Romo, A1
Jimenez-Diaz, VA1
Pace, WD1
Dagenais, GR1
Félix, C1
Guzik, TJ1
Hart, RG3
Muehlhofer, E1
Sharma, M1
Wang, W1
Wang, X3
Zhang, L2
Zhang, J1
Man, F1
Pan, Q1
Guo, L1
Faggioni, M1
Giustino, G2
Henry, TD2
Farhan, S1
Ariti, C2
Giacoppo, D1
Aquino, M1
Chandrasekhar, J1
Colombo, A3
Vogel, B1
Chieffo, A2
Kini, AS2
Van de Werf, F1
Chiou, JY1
Lai, YR1
Peng, CH1
Richman, IB1
Owens, DK1
Dalby, AJ1
Gottlieb, S1
Cyr, DD1
Magnus Ohman, E1
McGuire, DK3
Ruzyllo, W1
Wiviott, SD2
Winters, KJ1
Armstrong, PW1
White, HD1
Prabhakaran, D1
Roe, MT1
Madsen, M1
Egholm, G1
Jensen, LO1
Raungaard, B1
Mori, M1
Geirsson, A1
Kuliczkowski, W2
Radomski, M1
Gąsior, M1
Urbaniak, J1
Kaczmarski, J1
Mysiak, A1
Negrusz-Kawecka, M1
Bil-Lula, I1
von Schuckmann, LA1
Smith, D1
Hughes, MCB1
Malt, M1
van der Pols, JC1
Khosrotehrani, K1
Smithers, BM1
Green, AC1
Altundag, K1
Gils, C1
Reinholdt, B1
Andreassen, BD1
Brandslund, I2
Vinholt, PJ1
Chamberlain, JJ1
Johnson, EL1
Leal, S1
Rhinehart, AS1
Shubrook, JH1
Peterson, L1
Chen, F3
Kwiatkowski, J1
Halupczok-Żyła, J1
Bolanowski, M1
Kuliszkiewicz-Janus, M1
Murphy, K3
Cox, J3
Murawska, A3
Young, A2
Lay, M3
Sammons, E2
Waters, E2
Adler, A2
Bodansky, J2
Farmer, A2
McPherson, R2
Neil, A2
Simpson, D2
Peto, R2
Baigent, C2
Fernández-Ruiz, I1
Finamore, F1
Reny, JL1
Malacarne, S1
Fontana, P1
Sanchez, JC1
Thabah, MM1
Santulli, G1
Sugawara, M5
Goto, Y2
Yamazaki, T5
Teramoto, T5
Oikawa, S5
Shimada, K5
Uchiyama, S5
Ando, K5
Ishizuka, N5
Murata, M6
Yokoyama, K5
Uemura, Y2
Ikeda, Y6
Xing, Y1
Tan, KC1
Nitschmann, S1
Zheng, SL1
Roddick, AJ1
Tousoulis, D2
Khan, SU1
Ul Abideen Asad, Z1
Khan, MU1
Talluri, S1
Ali, F1
Shahzeb Khan, M1
Lone, AN1
Mookadam, F1
Krasuski, RA1
Kaluski, E1
Fortuni, F1
Crimi, G1
Gritti, V1
Mirizzi, AM1
Leonardi, S1
Ferrari, GM1
Vouillarmet, J1
Ye, S1
Lee, M1
Lee, D1
Ha, EH1
Chun, EM1
Van't Hof, JR1
Duval, S1
Misialek, JR1
Oldenburg, NC1
Jones, C1
Eder, M1
Luepker, RV1
Leggio, M1
Tiberti, C1
Mazza, A1
Luo, WH1
Guo, Y1
Huang, JW1
Zhang, PD1
Tonon, F1
Kedhi, E2
Carriero, A2
Faggiano, P1
Fattirolli, F2
Frisinghelli, A1
Piccioli, L1
Dasseni, N1
Silverii, MV1
Albricci, L1
D'Ambrosio, G1
Garrì, R1
Esposito, L1
Giallauria, F1
Seidu, S1
Kunutsor, SK1
Sesso, HD1
Gaziano, JM3
Buring, JE3
Roncaglioni, MC1
Khunti, K1
Harima, K1
Honda, S1
Mikami, K1
Kitajima, M1
Urushizaka, M1
Tomisawa, T1
Hagii, J1
Metoki, H1
Yasujima, M1
Osanai, T1
Marcolongo, M1
Plazak, ME1
Mouradjian, MT1
Watson, K1
Reed, BN1
Noel, ZR1
Devabhakthuni, S1
Gale, SE1
DiNicolantonio, JJ2
Serebruany, VL1
James, S1
Capranzano, P2
Capodanno, D4
Mogabgab, O1
Antman, EM1
Foody, JM1
Wang, TY3
Sabatine, MS1
Li, S3
Giugliano, RP1
Seçil, Y1
Ciftçi, Y1
Tokuçoğlu, F1
Beckmann, Y1
de Groot, NL1
Hagenaars, MP1
Smeets, HM1
Steyerberg, EW1
Siersema, PD1
van Oijen, MG1
Matthys, F1
De Backer, T1
De Backer, G1
Stichele, RV1
Stolarz-Skrzypek, K1
Bednarski, A1
Drozdz, D1
Czarnecka, D1
Patel, R1
Darlington, A2
Wilson, RE1
Muñiz-Lozano, A1
Desai, B2
Bender, N1
Sakariassen, KS1
Reilly, PA1
Lehr, T1
Haertter, S1
Ezekowitz, MD1
Nehmiz, G1
Wang, S2
Wallentin, L1
Rahmatullah, M1
Hossain, M1
Mahmud, A1
Sultana, N1
Rahman, SM1
Islam, MR1
Khatoon, MS1
Jahan, S1
Islam, F1
Kawamura, N1
Ito, Y1
Sasaki, M1
Iida, A1
Mizuno, M1
Ogasawara, N1
Funaki, Y1
Kasugai, K1
Lackland, DT1
Roccella, EJ1
Deutsch, AF1
Fornage, M1
George, MG1
Howard, G1
Kissela, BM1
Kittner, SJ1
Lichtman, JH1
Lisabeth, LD1
Schwamm, LH1
Smith, EE1
Towfighi, A1
Tisminetzky, M1
Joffe, S1
McManus, DD2
Darling, C1
Gore, JM3
Yarzebski, J2
Lessard, D2
Goldberg, RJ3
Kim, AJ1
Lim, HJ1
Ro, H1
Ko, KP1
Han, SY1
Chang, JH1
Lee, HH1
Chung, W1
Jung, JY1
Guo, X1
Zhang, Y2
Xu, G1
Zhou, X1
Li, L1
Tang, B1
Daels, FP1
Gaizauskas, A1
Rioja, J1
Varshney, AK1
Erkan, E1
Ozgok, Y1
Melekos, M1
de la Rosette, JJ1
Lin, CC1
Lai, MS1
Shau, WY1
Xie, M1
Shan, Z1
Chen, S1
Yang, W1
Bao, W1
Rong, Y1
Yu, X1
Hu, FB1
Liu, L2
Joseph, JM1
Johnson, PJ1
Wholey, DR1
Frederick, ML1
Kotsakis, GA1
Thai, A1
Ioannou, AL1
Demmer, RT1
Michalowicz, BS1
Wehbeh, A1
Tamim, HM1
Abu Daya, H1
Abou Mrad, R1
Badreddine, RJ1
Eloubeidi, MA1
Rockey, DC1
Barada, K1
Lee, SA1
Suh, JW1
Park, JJ1
Yoon, CH1
Cho, YS1
Youn, TJ1
Kim, SH1
Choi, DJ1
Gold, R1
Nelson, C1
Cowburn, S1
Bunce, A1
Hollombe, C1
Davis, J1
Muench, J1
Hill, C1
Mital, M1
Puro, J1
Perrin, N1
Nichols, G1
Turner, A1
Mercer, M1
Jaworski, V1
Howard, C1
Abiles, E1
Shah, A1
Dudl, J1
Chan, W1
DeVoe, J1
Paixao, AR1
Enriquez, JR1
Berry, JD1
Khera, A1
Das, SR2
de Lemos, JA2
Kontos, MC1
Zanders, MM1
van Herk-Sukel, MP1
Vissers, PA1
Herings, RM1
Haak, HR1
van de Poll-Franse, LV1
Siasos, G1
Oikonomou, E1
Zaromitidou, M1
Kioufis, S1
Kokkou, E1
Mourouzis, K1
Vlasis, K1
Vavuranakis, M1
Stone, PH1
Papavassiliou, AG1
Nakagawa, I1
Park, HS1
Yokoyama, S1
Wada, T1
Hironaka, Y1
Motoyama, Y1
Takayama, K1
Kichikawa, K1
Nakase, H1
Tchwenko, S1
Fleming, E1
Perry, GS1
Bell, DS1
Bhatia, N1
Santos, M1
Jones, LW1
Beckman, JA1
Penson, DF1
Morgans, AK1
Moslehi, J1
Katare, PB1
Banerjee, SK1
Barbieri, L2
Schaffer, A2
Marino, P1
Bellomo, G2
Meredith, IT1
Tanguay, JF1
Kereiakes, DJ2
Cutlip, DE2
Yeh, RW2
Garratt, KN1
Lee, DP1
Weaver, WD1
Holmes, DR2
Brindis, RG1
Trebacz, J1
Massaro, JM2
Hsieh, WH1
Mauri, L2
Secemsky, EA1
Normand, SL1
Gershlick, AH1
Rinaldi, MJ1
Camenzind, E1
Wijns, W1
Apruzzese, PK1
Song, Y1
Marrugat, J1
Elosua, R1
Grau, M1
Sayols-Baixeras, S1
Dégano, IR1
Litherland, C1
Kirtane, AJ1
Stone, GW1
Minematsu, K1
Matsumoto, M1
Sartori, C1
Soeiro, Ade M1
Mansur, Ade P1
Schaan, BD1
Caramelli, B1
Rochitte, CE1
Serrano, CV1
Garzillo, CL1
Calderaro, D1
Gualandro, DM1
Lima, EG1
Marcondes-Braga, FG1
Lima, FG1
Oliveira, FM1
Azevedo, FR1
Chauhan, H1
Salles, JE1
Soares, J1
Cardoso, JN1
Pellanda, LC1
Sacilotto, L1
Baracioli, L1
Bortolotto, LA1
César, LA1
Ochiai, ME1
Minami, MH1
Pinheiro, MB1
Moretti, MA1
Oliveira, MT1
Rezende, PC1
Lemos, PA1
Admoni, SN1
Lottenberg, SA1
Rocha, VZ1
Hueb, W1
Mathias, W1
Matsuo, K1
Cahoon, SS1
Yoshihara, K1
Shida, M1
Kakuda, M1
Adachi, S1
Moeini, A1
Machida, H1
Garcia-Sayre, J1
Ueda, Y1
Enomoto, T1
Mikami, M1
Roman, LD1
Sood, AK1
Lou, G1
Chen, J1
Xia, Y1
Aboonabi, A1
Singh, I1
Al-Ramahi, R1
Raddad, AR1
Rashed, AO1
Bsharat, A1
Abu-Ghazaleh, D1
Yasin, E1
Shehab, O1
Kokoska, LA1
Wilhelm, SM1
Garwood, CL1
Berlie, HD2
So, CH1
Eckman, MH1
Koohshekan, B1
Divsalar, A1
Makam, RC1
Erskine, N1
Ball, J1
Murff, HJ1
Grodzinsky, A1
Arnold, SV1
Sharma, P1
Gosch, K1
Jones, PG1
Chhatriwalla, AK1
Lind, M1
Graham, G1
Kosiborod, M1
Levine, GN1
Bakaeen, FG1
Zuliani Mauro, MF1
Mangione, JA1
Costa, JR1
Costa, R1
Piva E Mattos, LA1
Staico, R1
Feres, F1
Siqueira, D1
Sousa, A1
Abizaid, A1
Chen, DC1
Singh, GD1
Armstrong, EJ1
Waldo, SW1
Laird, JR1
Amsterdam, EA2
Serebruany, V1
Pokov, I1
Chesebro, J1
Badimon, J1
Airee, A1
Draper, HM1
Finks, SW1
Blaha, MJ3
Bansal, S1
Rouf, R1
Golden, SH1
Blumenthal, RS3
Defilippis, AP2
Rajec, J1
Kriska, M1
Vojtko, R1
Dukat, A1
Risnyovszki, Z1
Sapak, M1
Anfossi, G1
Russo, I1
Trovati, M1
Cerbone, AM2
Macarone-Palmieri, N1
Saldalamacchia, G1
Coppola, A1
Di Minno, G1
Rivellese, AA1
Price, HC1
Holman, RR1
Azuz, N1
Thomas, K2
Yaffe, Y1
Katz, M1
Weingarten, M1
Matalon, A1
Roffi, M1
Eberli, FR1
Suryadevara, S1
Younis, N1
Williams, S1
Soran, H1
Hebert, PR1
Schneider, WR1
Hennekens, CH5
Depta, JP1
Fonarow, GC1
Zhao, X1
Peacock, WF1
Stellos, K1
Bigalke, B1
Stakos, D1
Henkelmann, N1
Gawaz, M1
Araki, S1
Kashiwagi, A2
Kappagoda, CT1
Bauer, T1
Gitt, A1
Zahn, R1
Jünger, C1
Koeth, O1
Towae, F1
Bestehorn, K1
Senges, J1
Zeymer, U1
Liistro, F1
Fineschi, M1
Grotti, S1
Angioli, P1
Carrera, A1
Ducci, K1
Gori, T1
Falsini, G1
Pierli, C1
Bolognese, L1
Yamada, N1
Bernardo, E3
Vivas, D1
Sabaté, M3
Ferreiro, JL2
Ueno, M2
Jimenez-Quevedo, P3
Alfonso, F3
Bass, TA4
Macaya, C3
Fernandez-Ortiz, A3
Aroca García, D1
Gómez Rivas, P1
López Lax, MC1
Morel, O1
Kessler, L1
Ohlmann, P1
Bareiss, P1
Pignone, M1
Alberts, MJ2
Colwell, JA15
Cushman, M2
Inzucchi, SE1
Mukherjee, D1
Rosenson, RS1
Williams, CD1
Wilson, PW1
Kirkman, MS1
Lee, HY1
Tong, YP1
Xing, S1
Cooke, CE1
Tota-Maharaj, R1
Chakroun, T1
Elalamy, I1
Abderazek, F1
Chouchene, S1
Dridi, Z1
Gerotziafas, GT1
Hatmi, M1
Hassine, M1
Gamra, H1
Armstrong, C1
Sethi, A1
Parmar, HS1
Kumar, A1
Schattner, P1
Saunders, M1
Stanger, L1
Speak, M1
Russo, K1
Nicolucci, A2
Standl, E2
Poisson, S1
Johnston, SC1
Dharmashankar, K1
Sumner, S1
Charlton, RK1
Box, LC1
Zenni, M1
Guzman, LA1
Simpson, SH1
Mereu, L1
Chambers, T1
Ueno, H1
Koyama, H1
Mima, Y1
Fukumoto, S1
Tanaka, S1
Shoji, T2
Emoto, M1
Nishizawa, Y1
Inaba, M2
Pujol Lereis, VA1
Ameriso, S1
Povedano, GP1
Ameriso, SF1
Postula, M1
Kaplon-Cieslicka, A1
Rosiak, M1
Kondracka, A1
Serafin, A1
Filipiak, KJ1
Czlonkowski, A1
Opolski, G2
Janicki, PK1
Awad, HH1
Zubaid, M1
Alsheikh-Ali, AA1
Al Suwaidi, J1
Anderson, FA1
Jackson, AN1
Hume, AL1
Tang, WH1
Stitham, J1
Gleim, S1
Di Febbo, C1
Porreca, E1
Fava, C1
Tacconelli, S1
Capone, M1
Evangelista, V1
Levantesi, G1
Wen, L1
Martin, K1
Minuz, P1
Rade, J1
Patrignani, P1
Hwa, J1
Mongan, J1
Mieszczanska, HZ1
Smith, BH1
Messing, SP1
Phipps, RP1
Francis, CW1
Silverman, MG1
Budoff, MJ1
Rivera, JJ1
Raggi, P1
Shaw, LJ1
Berman, D1
Callister, T1
Rumberger, JA1
Rana, JS1
Nasir, K1
Kreutz, RP1
Nystrom, P1
Kreutz, Y1
Miao, J1
Kovacs, R1
Desta, Z1
Flockhart, DA1
Jin, Y1
Cao, J1
Fan, L1
Chen, T1
Hu, G1
Hu, Y1
Zhu, B1
Li, J1
Wang, H1
Li, X1
White, CL1
Szychowski, JM1
Roldan, A1
Benavente, MF1
Pretell, EJ1
Del Brutto, OH1
Kase, CS2
Arauz, A1
Meyer, BC1
Meissner, I1
Demaerschalk, BM1
McClure, LA1
Coffey, CS1
Pearce, LA1
Conwit, R1
Irby, LH1
Peri, K1
Pergola, PE1
Benavente, OR1
De Berardis, G1
Lucisano, G1
D'Ettorre, A1
Pellegrini, F1
Lepore, V1
Tognoni, G1
Siller-Matula, JM1
Strojek, K1
Kurzelewski, M1
Ostrowski, M1
Rabczenko, D1
Patrono, C2
Han, Y1
Jing, Q1
Yan, G1
Ma, Y1
Wang, G1
Chen, X1
Yang, L1
Zhu, G1
Liu, H1
Jiang, T1
O'Keefe, JH1
Lavie, CJ1
Lund, JL1
Stürmer, T1
Toft-Sørensen, H1
Miao, Z1
Jiang, L2
Wu, H1
Bao, Y1
Jiao, L1
Wu, J1
Hua, Y1
Zhu, J1
Zhu, F1
Ling, F1
Lin, YC1
Yang, CC1
Chen, YJ1
Peng, WC1
Li, CY1
Hwu, CM1
Tomaszuk-Kazberuk, A1
Kozuch, M1
Malyszko, J1
Bachorzewska-Gajewska, H1
Dobrzycki, S1
Musial, WJ1
Argay, M1
Koós, I1
Takács, I1
Dormaeva, I1
Meskó, A1
Zelkó, R1
Hankó, B1
Chiang, CE1
Wang, KL1
Ward, DR1
Novak, E1
Scott-Douglas, N1
Brar, S1
White, M1
Hemmelgarn, BR1
McCullough, PA1
Sandberg, KR1
Borzak, S1
Hudson, MP1
Garg, M1
Manley, HJ1
Marso, SP1
Hirsch, AT1
Ringleb, PA1
Hacke, W2
Topol, EJ2
Bouldin, MJ1
Low, AK1
Blackston, JW1
Duddleston, DN1
Holman, HE1
Hicks, GS1
Brown, CA1
Mateos-Cáreres, PJ1
García-Méndez, A1
Farré, J1
Sánchez de Miguel, L1
Gómez, J1
de Andres, R1
Rico, L1
Romero, J1
López-Farré, A1
Grand, A1
Thomas, T1
Nadackal, GT1
Eichenberger, A1
Pontiggia, L1
Beer, JH1
Kurth, T1
Berger, K1
Schaeffner, ES1
Brown, AF2
Mangione, CM2
Saliba, D1
Sarkisian, CA1
Dirkali, A1
Umans, VA1
López De La Iglesia, J1
Escudero Alvarez, S1
González García, AM1
Mencía Mieres, A1
García Andrés, LE1
Morán Fernández, B1
Gross, AG1
Gutierrez, PR1
Shapiro, MF1
Ali Raza, J1
Movahed, A1
Mohri, M1
Nesto, RW1
REID, J3
MACDOUGALL, AI1
ANDREWS, MM1
LIGHTBODY, TD1
LISTA, GA1
NUNEZ, OH1
VOZZI, IR1
HECHT, A1
GOLDNER, MG1
KABANCHIK, M1
LEVIN, H1
TUCHSZER, S1
SCHWEISHEIMER, W1
BARNESS, LA1
YOUNG, LN1
FENNELLY, JJ1
LASKER, N1
SMITH, LB1
CARLSON, LA1
OSTMAN, J1
Ridker, PM2
Montori, VM1
Bryant, SC1
O'Connor, AM1
Jorgensen, NW1
Walsh, EE1
Smith, SA1
Chua, DY1
Bakris, GL1
Esmatjes, E1
Castell, C1
Franch, J1
Puigoriol, E1
Hernáez, R1
Bueno, H1
INGLE, DJ1
Moses, JW1
Morice, MC1
Ludwig, J1
Spanos, V1
Louvard, Y1
Desmedt, B1
Di Mario, C1
Leon, MB1
Gohlke, H1
Schirmer, A1
Theobald, KH1
Camerini, A1
Chieffo, C1
Griffo, R1
Comaschi, M1
Gattone, M1
Mannucci, E1
Faglia, E1
Giorda, C1
Biorci, ML1
Hennis, A1
Wu, SY1
Nemesure, B1
Leske, MC1
de Gaetano, G2
Lim, HS1
Blann, AD1
Lip, GY2
Bradshaw, PJ1
Jamrozik, K1
Gilfillan, I1
Thompson, PL1
Sicras Mainar, A1
Ruiz Riera, R1
Frías Garrido, X1
Navarro Artieda, R1
Barquero Romero, J1
Masero Carretero, A1
Pérez Miranda, M1
González-Clemente, JM1
Barahona, MJ1
Giménez-Pérez, G1
Mauricio, D1
Diogène, E1
Agustí, A1
Critchley, J1
Liu, J1
Zhao, D1
Wei, W1
Capewell, S1
Fulcher, GR1
Amarena, JV1
Conner, GW1
Gilbert, RE1
Hankey, GJ1
Gage, BF1
van Walraven, C1
Pearce, L1
Koudstaal, PJ1
Boode, BS1
Petersen, P1
Knatterud, GL1
Pfeffer, MA1
Hirsh, J1
Damci, T1
Kultursay, H1
Oguz, A1
Pehlivanoglu, S1
Tokgozoglu, L1
Schnell, O1
McLaurin, EY1
Holliday, SL1
Williams, P1
Brey, RL1
Edmisson, KW1
Shanks, M1
Holmes, DT1
Cermakova, L1
Frohlich, J1
Righetti, A1
De Moerloose, P1
Philippe, J1
Mainous, AG1
Koopman, RJ1
Diaz, VA1
Fujita, S1
Kawaguchi, T1
Uehara, T1
Fukushima, K1
Abaci, A2
Caliskan, M1
Bayram, F1
Yilmaz, Y1
Cetin, M1
Unal, A1
Cetin, S1
Cimminiello, C1
Ramírez, C2
Hernández, R2
Bañuelos, C2
Costa, MA2
Lepäntalo, A1
Mikkelsson, J1
Reséndiz, JC1
Viiri, L1
Backman, JT1
Kankuri, E1
Karhunen, PJ1
Lassila, R1
Piepoli, MF1
Klutmann, M1
Tillmanns, C1
Gulba, DC1
Vaeth, PA1
Stanek, HG1
Dobbins, RL1
Drzewoski, J1
Sawer-Szewczyk, J1
Stepień, A1
Olszewski, A1
Liniarski, M1
Mignot, A1
Sosner, P1
Llaty, P1
Herpin, D1
Takahashi, S1
Ushida, M1
Komine, R1
Shimizu, A1
Uchida, T1
Ishihara, H1
Shibano, T1
Watanabe, G1
Kurukulasuriya, LR1
Govindarajan, G1
Sowers, J1
Harding, JJ2
Ganea, E1
Ambrosi, P1
Villani, P1
Bouvenot, G1
Pongwecharak, J1
Maila-ead, C1
Sakulthap, J1
Sripanitkulchai, N1
Uzu, T1
Isshiki, K1
Kanasaki, M1
Hirata, K1
Soumura, M1
Nakazawa, J1
Takaya, K1
Isono, M1
Nishimura, M1
Shikano, T1
Nishio, T1
Tomita, K1
Arimura, T1
Camargo, EG1
Gross, JL1
Weinert, LS1
Lavinsky, J1
Silveiro, SP1
Marzocchi, A1
Saia, F1
Piovaccari, G1
Manari, A1
Aurier, E1
Benassi, A1
Cremonesi, A1
Percoco, G1
Varani, E1
Magnavacchi, P1
Guastaroba, P1
Grilli, R1
Maresta, A1
Shekelle, P1
Vijan, S2
Sicras-Mainar, A1
Navarro-Artieda, R1
Rejas-Gutiérrez, J1
Fernández-de-Bobadilla, J1
Frías-Garrido, X1
Ruiz-Riera, R1
Hammad, A1
Jaber, LA1
Türkoğlu, S1
Persell, SD1
Denecke-Dattalo, TA1
Dunham, DP1
Baker, DW1
McCarren, M1
Lee, SW1
Park, SW1
Yun, SC1
Park, DW1
Lee, CW1
Hong, MK1
Ko, JK1
Park, JH1
Lee, JH1
Choi, SW1
Seong, IW1
Cho, YH1
Kim, JH1
Chun, KJ1
Park, SJ1
Nielsen, AA1
Veien, KT1
Jørgensen, LG1
Buck, TC1
Christensen, C1
Gasparyan, AY1
Watson, T1
Wasilewska, A1
Strakosch, CR1
Jefferys, DB1
Keen, H1
Giugliano, D5
Kornitzer, M1
de Boer, AC1
Genton, E1
Turpie, AG1
Waitzman, MB2
Cornelius, LM1
Evatt, BL1
McCarty, MF1
Jørgensen, KA1
Kaplan, H1
Cornelius, L1
Evatt, B1
Hunt, B1
Robertson, RP2
Vierhapper, H1
Bratusch-Marrain, P1
Waldhäusl, W1
Nowotny, P1
Panzer, S1
Liang, JZ1
Vesterqvist, O1
Gréen, K1
Gendeleka, GF2
Gruzina, EA2
Ek, I1
Thunell, S1
Blombäck, M1
Halushka, PV3
Morin, RJ1
Chen, AF1
Narayanan, AS1
Raye, C1
Moss, RA1
Srikantaiah, MV1
Barajas, L1
Sgamboto, S1
Coppola, L1
Misso, L1
Torella, R3
Amado Señaris, JA1
Garcia-Conde Bru, J1
Merino Sanchez, J1
Benet Monforte, I1
Porta, M1
Diamond, GA1
Forrester, JS1
White, GL1
Marouf, AA1
González, ER1
Tornvall, G1
Allgén, LG1
Prince, RL1
Larkins, RG1
Alford, FP1
D'Onofrio, F1
McRae, JR1
Metz, SA1
Seino, Y1
Usami, M1
Nakahara, H1
Takemura, J1
Nishi, S1
Ishida, H1
Ikeda, M1
Imura, H1
Spesivtseva, VG1
Kakhnovskiĭ, IM1
Mamaeva, GG1
Golubiatnikova, GA2
Seid-Guseĭnov, AA1
Khosla, PK1
Seth, V1
Tiwari, HK1
Saraya, AK1
Balabolkin, MI1
Koroleva, TV1
Titova, GP1
Passariello, N1
Cerciello, T1
Varricchio, M2
Sgambato, S1
Tindall, H1
Paton, RC2
Zuzel, M1
McNicol, GP1
Yudkin, JS3
Bissé, E1
Huaman-Guillen, P1
Wieland, H1
Hansson, L1
Zanchetti, A1
Daví, G1
Prior, MJ1
Prout, T1
Miller, D2
Ewart, R1
Kumar, D1
Heath, MM1
Rixon, KC1
Chew, EY1
Klein, ML1
Ferris, FL1
Remaley, NA1
Murphy, RP1
Chantry, K1
Hoogwerf, BJ1
Rockwood, K1
Ebly, E1
Hachinski, V1
Hogan, D1
Goodfield, M1
Gillum, RF1
Gascón Ramón, G1
Bertomeu i Blanch, F1
Baño Aracil, M1
Madrigal, JA1
Stampfer, MJ1
Tracy, RP1
Passa, P1
Eccles, M1
Freemantle, N1
Mason, J1
Lim, LL1
Tesfay, GM1
Heller, RF1
Nordt, TK1
Moser, M1
Kohler, B1
Ruef, J1
Peter, K1
Kübler, W1
Bode, C1
Herlitz, J1
Malmberg, K1
Mahaffey, KW1
Harrington, RA1
Simoons, ML1
Granger, CB1
Graffagnino, C1
Laskowitz, DT1
Miller, JM1
Sloan, MA1
Berdan, LG1
MacAulay, CM1
Lincoff, AM1
Deckers, J1
Califf, RM1
Chowdhury, TA1
Lasker, SS1
Dyer, PH1
Fisher, M1
Steinberg, H1
Ajani, UA1
Lotufo, PA1
Holroyd-Leduc, JM1
Kapral, MK1
Austin, PC1
Tu, JV1
Hildebrandt, PR1
Snorgaard, O1
Melchior, TM1
Seibaek, MB1
Torp-Pedersen, CT1
Poulter, N1
Rolka, DB1
Fagot-Campagna, A1
Narayan, KM1
Abrahamian, H1
George, PB1
Tobin, KJ1
Corpus, RA1
Devlin, WH1
O'Neill, WW1
Doughty, M1
Mehta, R1
Bruckman, D1
Das, S1
Karavite, D1
Tsai, T1
Eagle, K1
Bredie, SJ1
Wollersheim, HC1
Verheugt, FW1
Thien, T1
Krein, SL1
Pogach, LM1
Hogan, MM1
Kerr, EA1
Kiberd, BA1
Packham, MA1
Matsuo, T3
Ohki, Y1
Fowler, PD1
Cacciapuoti, F1
Jones, RL1
Peterson, CM1
Vergroesen, AJ1
Gottenbos, JJ1
ten Hoor, F1
Aznar, J1
Martínez-Sausor, V1
Valles, J1
Villa, P1
Vinceneux, P1
Lubetski, D1
Kahn, MF1
Micossi, P1
Pontiroli, AE1
Baron, SH1
Tamayo, RC1
Lengel, F1
Bevilacqua, M1
Raggi, U1
Norbiato, G1
Foà, PP1
Ohoki, Y1
Sarji, K1
Levine, J1
Sagel, J2
Nair, RM1
Fisherman, EW1
Cohen, GN1
Crook, L1
Laimins, M1
Caplin, I1
Terres, W1
Hamm, CW1
Ruchelka, A1
Weilepp, A1
Kupper, W1
Sivenius, J1
Laakso, M1
Riekkinen, P1
Smets, P1
Lowenthal, A1
Bundlie, SR1
Delbridge, L1
Ellis, CS1
Robertson, K1
Lequesne, LP1
Baluda, VP1
Lukoianova, TI1
Deianov, I1
Violi, F1
Alessandri, C1
Ghiselli, A1
Germani, M1
Caliendo, C1
Censi, C1
Servi, M1
Balsano, F1
Gerrard, JM1
Taback, S1
Singhroy, S1
Docherty, JC1
Kostolansky, I1
McNicol, A1
Kobrinsky, NL1
McKenzie, JK1
Rowe, R1
Awata, T1
Kadowaki, S1
Winocour, PD1
Kinlough-Rathbone, RL1
Mustard, JF1
DiMinno, G1
Silver, MJ1
Murphy, S1
Udvardy, M1
Török, I1
Rak, K1
Skrha, J1
Svacina, S1
Hilgertová, J1
Srámková, J1
Hovorka, R1
Perusicová, J1
Masek, Z1
Páv, J1
Bingham, SF1
Hun-Opfer, C1
Mata-Segreda, JF1
Katayama, S1
Maruno, Y1
Omoto, A1
Kawazu, S1
Ishii, J1
Mayfield, R1
Hamazaki, T1
Hasunuma, K1
Kobayashi, S1
Shishido, H1
Yano, S1
Okuma, M1
Wood, L1
Kågedal, B1
Laurell, S1
Rooth, G1
el-Dakhakhny, M1
el-Sayed, M1
Hussey, HH1
Hawtrey, CE1
Williams, JJ1
Schmidt, JD1
Kwaan, HC1
Cruz, S1
Suwanwela, N1
Dobbie, JG1
Feldman, JM1
Kelley, WN1
Lebovitz, HE1
Powell, ED1
Field, RA1

Clinical Trials (49)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226]Phase 415,480 participants (Actual)Interventional2005-03-31Active, not recruiting
A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease[NCT01852175]110 participants (Actual)Interventional2012-01-31Completed
Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938]Phase 260 participants (Anticipated)Interventional2022-11-30Recruiting
Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560]Phase 34,415 participants (Actual)Interventional2015-12-20Active, not recruiting
Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985]Phase 38,410 participants (Actual)Interventional2011-02-28Completed
Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care[NCT05155137]Phase 312,268 participants (Anticipated)Interventional2021-12-20Recruiting
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]Phase 327,395 participants (Actual)Interventional2013-02-28Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]Phase 49,006 participants (Actual)Interventional2015-07-31Completed
Performance du TiVi Pour évaluer la réactivité Microcirculatoire de la Peau à l'Application d'un Courant Galvanique, Effet de l'Aspirine[NCT03357367]830 participants (Actual)Interventional2018-02-08Completed
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial[NCT05283356]Phase 41,206 participants (Anticipated)Interventional2022-01-21Recruiting
The Impact of Meal Timing on Neurovascular Control in Adults[NCT04133701]34 participants (Actual)Interventional2022-02-02Completed
Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489]Phase 49,930 participants (Anticipated)Interventional2023-03-09Recruiting
Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883]1,120 participants (Anticipated)Interventional2020-06-01Recruiting
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II[NCT05702463]Phase 130 participants (Anticipated)Interventional2023-06-13Recruiting
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes: APPEASED Study Phase 1[NCT05105919]Early Phase 150 participants (Anticipated)Interventional2021-08-26Recruiting
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526]Phase 4450 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849]Phase 410,000 participants Interventional2005-03-31Recruiting
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035]1,496 participants (Actual)Observational2015-03-22Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268]Phase 472 participants (Actual)Interventional2019-04-24Completed
Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156]4,118 participants (Anticipated)Interventional2019-03-31Not yet recruiting
A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643]Phase 3220 participants (Actual)Interventional2009-04-30Completed
Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics[NCT02299791]4,856 participants (Actual)Interventional2010-09-30Completed
Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients[NCT03740035]4 participants (Actual)Observational2018-08-13Terminated (stopped due to Pl left institution)
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]Phase 425,682 participants (Actual)Interventional2009-10-31Completed
Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401]Phase 4390 participants (Anticipated)Interventional2019-08-22Suspended (stopped due to Testing supplies unavailable.)
Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989]Phase 42,106 participants (Anticipated)Interventional2020-01-01Active, not recruiting
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127]5,031 participants (Actual)Observational2009-06-30Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]280 participants (Actual)Observational2014-06-30Completed
Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470]Phase 485 participants (Actual)Interventional2009-09-30Completed
Effects of Pioglitazone on Platelet Function[NCT00861341]Phase 240 participants (Actual)Interventional2008-12-31Completed
Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578]Phase 42,077 participants (Actual)Interventional2006-06-30Completed
Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study[NCT01480804]48 participants (Actual)Interventional2006-11-30Completed
Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study[NCT01486290]52 participants (Actual)Interventional2007-07-31Completed
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330]Phase 440 participants (Actual)Interventional2016-06-30Completed
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]Phase 4150 participants (Actual)Interventional2007-09-30Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]Phase 4190 participants (Anticipated)Interventional2010-06-30Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]Phase 4200 participants (Anticipated)Interventional2005-03-31Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]Phase 420 participants (Actual)Interventional2009-06-30Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]Phase 480 participants (Actual)Interventional2008-11-30Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]Phase 3200 participants (Actual)Interventional2005-06-30Completed
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]Phase 480 participants (Actual)Interventional2009-05-31Completed
[NCT00000151]Phase 30 participants Interventional1979-12-31Completed
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665]30 participants (Actual)Interventional2016-03-31Completed
Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769]Phase 19 participants (Actual)Interventional2017-06-01Completed
Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?[NCT00462436]Phase 235 participants (Anticipated)Interventional2007-02-28Completed
Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University[NCT03266328]117 participants (Anticipated)Observational2017-09-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Any Incident Gastrointestinal (GI) Tract Cancer (Aspirin Comparison Only)

"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin157
Placebo Aspirin158

Number of Participants With Combined End-point of Serious Vascular Events (SVEs) or Revascularizations

"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin833
Placebo Aspirin936
Omega-3882
Placebo Omega-3887

Number of Participants With Event: Any Cancer

"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin897
Placebo Aspirin887
Omega-3894
Placebo Omega-3890

Number of Participants With Event: Atrial Fibrillation (Omega-3 Comparison Only)

Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Omega-3166
Placebo Omega-3135

Number of Participants With Event: Breast Cancer

Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin97
Placebo Aspirin96
Omega-3103
Placebo Omega-390

Number of Participants With Event: Genitourinary Cancer

Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin332
Placebo Aspirin294
Omega-3323
Placebo Omega-3303

Number of Participants With Event: Hematological Cancer

Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin88
Placebo Aspirin86
Omega-394
Placebo Omega-380

Number of Participants With Event: Melanoma

Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin50
Placebo Aspirin59
Omega-355
Placebo Omega-354

Number of Participants With Event: Other Arrhythmia (Omega-3 Comparison Only)

Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Omega-383
Placebo Omega-399

Number of Participants With Event: Other Cancer

Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin25
Placebo Aspirin30
Omega-323
Placebo Omega-332

Number of Participants With Event: Other Gastrointestinal Cancer (Aspirin Comparison Only)

Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin87
Placebo Aspirin82

Number of Participants With Event: Respiratory Cancer

Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin101
Placebo Aspirin103
Omega-3104
Placebo Omega-3100

Number of Participants With Event: Unspecified Cancer

Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin26
Placebo Aspirin31
Omega-325
Placebo Omega-332

Number of Participants With Fatal Event: All Stroke

Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin38
Placebo Aspirin34
Omega-335
Placebo Omega-337

Number of Participants With Fatal Event: All-cause Mortality

'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin748
Placebo Aspirin792
Omega-3752
Placebo Omega-3788

Number of Participants With Fatal Event: Cancer

Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin309
Placebo Aspirin315
Omega-3305
Placebo Omega-3319

Number of Participants With Fatal Event: Coronary

Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin105
Placebo Aspirin122
Omega-3100
Placebo Omega-3127

Number of Participants With Fatal Event: External Cause

Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin18
Placebo Aspirin21
Omega-317
Placebo Omega-322

Number of Participants With Fatal Event: Other Medical

Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin126
Placebo Aspirin157
Omega-3158
Placebo Omega-3125

Number of Participants With Fatal Event: Other Vascular

Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin67
Placebo Aspirin70
Omega-361
Placebo Omega-376

Number of Participants With Fatal Event: Respiratory

Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin82
Placebo Aspirin69
Omega-373
Placebo Omega-378

Number of Participants With Fatal Event: Unknown Cause

Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin3
Placebo Aspirin4
Omega-33
Placebo Omega-34

Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)

"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin314
Placebo Aspirin245

Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)

"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years

InterventionParticipants (Count of Participants)
Aspirin658
Placebo Aspirin743
Omega-3689
Placebo Omega-3712

Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP)

The primary end-point of the study was the comparison in the platelet reactivity index (PRI%) determined by vasodilator-stimulated phosphoprotein (VASP) at 1 week between prasugrel and ticagrelor. (NCT01852175)
Timeframe: 1 week

InterventionPRI% (Least Squares Mean)
Prasugrel32.1
Ticagrelor32.6

Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)

A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 2 hours after loading dose. (NCT01852175)
Timeframe: 2 hours

InterventionPRI% (Least Squares Mean)
Prasugrel13.4
Ticagrelor15.6

Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)

A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 24 hours after loading dose. (NCT01852175)
Timeframe: 24 hours

InterventionPRI% (Least Squares Mean)
Prasugrel14.2
Ticagrelor26.4

All-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg313
Rivaroxaban 5mg + Aspirin Placebo366
Rivaroxaban Placebo + Aspirin 100mg378

All-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg282

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg389
Rivaroxaban 5mg + Aspirin Placebo453
Rivaroxaban Placebo + Aspirin 100mg516

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg329
Rivaroxaban 5mg + Aspirin Placebo397
Rivaroxaban Placebo + Aspirin 100mg450

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg379
Rivaroxaban 5mg + Aspirin Placebo448
Rivaroxaban Placebo + Aspirin 100mg496

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg353

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg288
Rivaroxaban 5mg + Aspirin Placebo255
Rivaroxaban Placebo + Aspirin 100mg170

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg138

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor141
Aspirin + Ticagrelor250

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor135
Aspirin + Ticagrelor137

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both

Number of patients indicated for ACE/ARB and statin who had an active prescription for both, as a proportion of patients indicated for ACE/ARB and statin. (NCT02299791)
Timeframe: Percent of clinic patients prescribed guideline-concordant cardioprotective medications, as of the 1st day of each month, from up to 36 months

InterventionParticipants (Count of Participants)
Early Intervention1279
Late Implementation1318

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES1.70
Propensity-matched BMS2.61

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.69
DES 12-month DAPT1.45

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.40
DES 12-month DAPT1.35

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.03
BMS 12-month DAPT0.90

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.09
BMS 12-month DAPT1.05

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.74
DES 12-month DAPT1.88

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.53
DES 12-month DAPT1.57

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES11.37
Propensity-matched BMS13.24

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.04
BMS 12-month DAPT4.69

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.68
BMS 12-month DAPT5.48

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT5.62
DES 12-month DAPT6.49

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT4.34
DES 12-month DAPT5.92

Percent Platelet Aggregation Induced by Arachidonic Acid

Platelet aggregation was performed by the turbidimetric method of Born with simultaneous measurement of ATP release using a Chrono-log Lumi-Aggregometer with AGGRO/LINK for Windows Software version 5.1.6. Platelet rich plasma was placed in a silicone-coated cuvette with constant stirring at 1200 rpm using a siliconized stir bar for measurement of aggregation and ATP release. Aggregation was initiated using arachidonic acid (0.5 mM). At each time point the results are shown for maximum percent aggregation with arachidonic acid for all subjects. Sample 1 was obtained at baseline (BL). Sample 2 was drawn on the same day after ingestion of a single dose of 30 mg of pioglitazone. Sample 3 was obtained 6-9 days later after the subject had ingested a single 81 mg dose of aspirin (ASA), and sample 4 was drawn later that day after ingestion of 30 mg of pioglitazone. (NCT00861341)
Timeframe: at baseline and days 6-9

Interventionmaximum percentage aggregation (Mean)
Sample 1Sample 2Sample 3Sample 4
Pioglitazone With or Without 81mg Aspirin80906029

Percent Platelet Aggregation Induced by Collagen

Platelet aggregation was performed by the turbidimetric method of Born with simultaneous measurement of ATP release using a Chrono-log Lumi-Aggregometer with AGGRO/LINK for Windows Software version 5.1.6. Platelet rich plasma was placed in a silicone-coated cuvette with constant stirring at 1200 rpm using a siliconized stir bar for measurement of aggregation and ATP release. Aggregation was initiated using collagen (2ug.mL). At each time point the results are shown for maximum percent aggregation with collagen for all subjects. Sample 1 was obtained at baseline (BL). Sample 2 was drawn on the same day after ingestion of a single dose of 30 mg of pioglitazone. Sample 3 was obtained 6-9 days later after the subject had ingested a single 81 mg dose of aspirin (ASA), and sample 4 was drawn later that day after ingestion of 30 mg of pioglitazone. (NCT00861341)
Timeframe: baseline and day 6-9

Interventionmaximum percentage aggregation (Mean)
Sample 1Sample 2Sample 3Sample 4
Pioglitazone With or Without 81mg Aspirin89938378

Reviews

99 reviews available for aspirin and Diabetes Mellitus

ArticleYear
Is meta-analysis the optimal method to decide the duration of antiplatelet therapy in diabetic patients treated with drug‑eluting stenting?
    Polish archives of internal medicine, 2021, 09-30, Volume: 131, Issue:9

    Topics: Aspirin; Diabetes Mellitus; Humans; Pharmaceutical Preparations; Platelet Aggregation Inhibitors; St

2021
Aspirin for the prevention of pre-eclampsia in women with pre-existing diabetes: Systematic review.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2022, Volume: 62, Issue:1

    Topics: Aspirin; Diabetes Mellitus; Female; Humans; Pre-Eclampsia; Pregnancy

2022
Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis.
    Cancer medicine, 2022, Volume: 11, Issue:4

    Topics: Aspirin; Cohort Studies; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;

2022
Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk.
    Diabetes & metabolic syndrome, 2022, Volume: 16, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Heart Disease Risk Factors; Humans; Primary Pre

2022
Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:9

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation I

2022
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:6

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Gastrointestinal Hemorrhage; Humans; Intr

2022
Aspirin for Primary Prevention of Cardiovascular Diseases: "WALTZ" with the Evidence.
    Current cardiology reports, 2022, Volume: 24, Issue:9

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention; Risk Factors

2022
In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases.
    European journal of pharmacology, 2022, Oct-15, Volume: 932

    Topics: Amino Acids; Aspirin; Diabetes Mellitus; Humans; Insulins; Noncommunicable Diseases; Peptides; Polye

2022
Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes.
    Diabetes research and clinical practice, 2022, Volume: 191

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention; Risk Assessment

2022
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Current vascular pharmacology, 2023, Volume: 21, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Prim

2023
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
    Thrombosis and haemostasis, 2019, Volume: 119, Issue:10

    Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D

2019
Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study.
    Diabetologia, 2020, Volume: 63, Issue:5

    Topics: Animals; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Fatty Acids, Omega-3; Female; Humans;

2020
Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis.
    Primary care diabetes, 2020, Volume: 14, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar

2020
Antiplatelet therapies in diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Humans; Platelet Aggregation Inhib

2020
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis.
    Diabetes care, 2020, Volume: 43, Issue:5

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis

2020
Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
    Current cardiology reports, 2020, 05-29, Volume: 22, Issue:7

    Topics: Aged; Aspirin; Cardiovascular Diseases; Case-Control Studies; Diabetes Complications; Diabetes Melli

2020
The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:2

    Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Dr

2021
Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo
    Medicine, 2021, Apr-16, Volume: 100, Issue:15

    Topics: 4-Hydroxycoumarins; Aged; Aspirin; Atrial Fibrillation; Diabetes Mellitus; Diabetic Cardiomyopathies

2021
Aspirin for Primary Prevention.
    The Medical clinics of North America, 2017, Volume: 101, Issue:4

    Topics: Age Factors; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Diabetes Mellitus; Gastrointest

2017
The pathogenesis and available prevention options in patients with diabetic thrombophilia.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2018, Volume: 27, Issue:10

    Topics: Aspirin; Blood Coagulation; Diabetes Mellitus; Fibrinolysis; Humans; Hypoglycemic Agents; Thrombophi

2018
[Importance of acetylsalicylic acid in primary prevention : ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al.]
    Der Internist, 2019, Volume: 60, Issue:2

    Topics: Aspirin; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primary Prevention

2019
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    JAMA, 2019, Jan-22, Volume: 321, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Hemorrhage; Hum

2019
Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis.
    European journal of preventive cardiology, 2020, Volume: 27, Issue:19

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega

2020
    European journal of preventive cardiology, 2019, Volume: 26, Issue:15

    Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Humans; Platelet Aggregation In

2019
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
    Cardiovascular diabetology, 2019, 06-03, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases;

2019
An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease.
    Expert review of cardiovascular therapy, 2019, Volume: 17, Issue:8

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Practice Guide

2019
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.
    Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:3

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Diabetic Angiopat

2013
Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
    European journal of preventive cardiology, 2014, Volume: 21, Issue:3

    Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus; Evidence-Bas

2014
[Prevention of atherosclerosis in children--the role of statins and aspirin].
    Przeglad lekarski, 2013, Volume: 70, Issue:2

    Topics: Adult; Aspirin; Atherosclerosis; Child; Comorbidity; Diabetes Mellitus; Dyslipidemias; Humans; Hydro

2013
Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.
    Stroke, 2014, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Air Pollution; American Heart Association;

2014
Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Placebos; Publication Bia

2014
Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.
    Circulation, 2016, Feb-02, Volume: 133, Issue:5

    Topics: Aged; Androgen Antagonists; Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diabetes

2016
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
    Current topics in medicinal chemistry, 2016, Volume: 16, Issue:19

    Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride;

2016
The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 83

    Topics: Antioxidants; Aspirin; Blood Platelets; Diabetes Mellitus; Humans; Thrombosis; Treatment Outcome

2016
Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis.
    Diabetes research and clinical practice, 2016, Volume: 120

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Complications; D

2016
Aspirin resistance: disparities and clinical implications.
    Pharmacotherapy, 2008, Volume: 28, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Coronary Artery Bypass; Diabetes Mellitus;

2008
A practical "ABCDE" approach to the metabolic syndrome.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:8

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diet Therapy; Early Diagnosis; Evidence-Based M

2008
Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome.
    Current vascular pharmacology, 2008, Volume: 6, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Humans; Metabolic Syndrome; Pl

2008
Diabetes, vascular complications and antiplatelet therapy: open problems.
    Acta diabetologica, 2009, Volume: 46, Issue:4

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Interactions; Drug Resistance;

2009
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.
    Diabetes care, 2009, Volume: 32, Issue:4

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Ac

2009
Diabetes and acute coronary syndromes.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia

2009
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O

2009
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:11

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Fibrinolytic Age

2009
Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment.
    Journal of general internal medicine, 2009, Volume: 24, Issue:11

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Judgment; Male; Primary Prevent

2009
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
    Atherosclerosis, 2010, Volume: 212, Issue:2

    Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D

2010
A practical approach to the metabolic syndrome: review of current concepts and management.
    Current opinion in cardiology, 2010, Volume: 25, Issue:5

    Topics: Aspirin; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndro

2010
Updated recommendations on daily aspirin use in patients with diabetes.
    American family physician, 2010, Dec-15, Volume: 82, Issue:12

    Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Diabetes Mellitus; Dose-Response Relationship,

2010
Prevention of stroke following transient ischemic attack.
    Current atherosclerosis reports, 2011, Volume: 13, Issue:4

    Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin

2011
Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.
    Journal of general internal medicine, 2011, Volume: 26, Issue:11

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar

2011
Quality of care in diabetes: understanding the guidelines.
    The American journal of the medical sciences, 2002, Volume: 324, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Clinical Trials as Topic; Diabetes

2002
[Treatment of coronary insufficiency in diabetics: Part 2: acute coronary insufficiency].
    Annales de cardiologie et d'angeiologie, 1999, Volume: 48, Issue:2

    Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiot

1999
[Antiaggregation: aspirin].
    Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:1

    Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Di

2003
Current concepts of cardiovascular diseases in diabetes mellitus.
    International journal of cardiology, 2003, Volume: 89, Issue:2-3

    Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus

2003
[Primary and secondary prevention of coronary artery disease].
    Fukuoka igaku zasshi = Hukuoka acta medica, 2003, Volume: 94, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir

2003
The platelet in diabetes: focus on prevention of ischemic events.
    Diabetes care, 2003, Volume: 26, Issue:7

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans;

2003
Diabetes and chronic kidney disease: tragedy and challenge.
    Blood purification, 2004, Volume: 22, Issue:1

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Blood Glucose; Calcium Channel Blocke

2004
Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
    The Medical journal of Australia, 2004, 09-20, Volume: 181, Issue:S6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiova

2004
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
    Circulation, 2004, Oct-19, Volume: 110, Issue:16

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie

2004
Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges.
    Diabetes care, 2004, Volume: 27, Issue:11

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors

2004
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
    Archives of internal medicine, 2004, Oct-25, Volume: 164, Issue:19

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia

2004
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
    MMW Fortschritte der Medizin, 2004, Sep-02, Volume: 146, Issue:35-36

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon

2004
Multidimensional pharmacologic strategies for diabetes.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspir

2005
[Should we treat all diabetic patients with aspirin in primary prevention?].
    Revue medicale suisse, 2005, Jun-01, Volume: 1, Issue:22

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Primar

2005
Exercise rehabilitation in heart disease: the real "polypill" for primary and secondary prevention.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2005, Volume: 64, Issue:2

    Topics: Aspirin; Chronic Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise;

2005
[Management of hypertension in patients with diabetes].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:6 Pt 2

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non

2006
Stroke prevention in diabetes and obesity.
    Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular

2006
Protection against glycation and similar post-translational modifications of proteins.
    Biochimica et biophysica acta, 2006, Volume: 1764, Issue:9

    Topics: Aspirin; Carbohydrates; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced;

2006
[Coronary heart disease in patients with diabetes mellitus].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarke

2006
Antiplatelet therapy for primary prevention in diabetes.
    Diabetes & metabolism, 2006, Volume: 32 Spec No2

    Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diab

2006
[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications].
    Arquivos brasileiros de endocrinologia e metabologia, 2007, Volume: 51, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies

2007
Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
    Neurology, 2007, Aug-07, Volume: 69, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Cohort Stu

2007
Quality indicators for the care of diabetes mellitus in vulnerable elders.
    Journal of the American Geriatrics Society, 2007, Volume: 55 Suppl 2

    Topics: Aged; Aspirin; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; Frail Elderly; Gl

2007
[Use of aspirin in diabetic patients].
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2007, Volume: 7 Suppl 2

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Male; Platelet Aggregation Inhi

2007
The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
    Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Heart Failure; Humans; Hyperte

2008
Chemistry, measurement, and clinical significance of platelet specific proteins.
    Critical reviews in clinical laboratory sciences, 1982, Volume: 18, Issue:2

    Topics: Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Coagulation; Blood Coagulation Factors; Blood P

1982
Platelets, prostaglandins and thrombotic disorders.
    Clinics in haematology, 1981, Volume: 10, Issue:2

    Topics: Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Coronary Disease; Cyclic AMP

1981
Studies on the biological balance between thromboxanes and prostacyclins in relation to the platelet-vessel wall interaction.
    Danish medical bulletin, 1982, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Blood Platelets; Blood Vessels; Child; Diabetes Mel

1982
Prostaglandins, glucose homeostasis, and diabetes mellitus.
    Annual review of medicine, 1983, Volume: 34

    Topics: Anti-Inflammatory Agents; Arachidonic Acids; Aspirin; Blood Glucose; Diabetes Mellitus; Glucagon; Ho

1983
Platelet function in diabetes mellitus.
    British journal of haematology, 1980, Volume: 44, Issue:4

    Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Diabetes Mellitus; D

1980
[Arachidonic acid metabolism and platelet function in diabetics (author's transl)].
    Sangre, 1981, Volume: 26, Issue:3

    Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Diabetes Mellitus; Epoprostenol; Humans; Imid

1981
Prostaglandins and the alpha-cell.
    Prostaglandins and medicine, 1981, Volume: 6, Issue:3

    Topics: Albuterol; Animals; Arginine; Aspirin; Blood Glucose; Diabetes Mellitus; Furosemide; Glucagon; Guine

1981
Antiplatelet agents in the prevention of diabetic vascular complications.
    Diabetes/metabolism reviews, 1993, Volume: 9, Issue:3

    Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Hum

1993
How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
    BMJ (Clinical research ed.), 1993, May-15, Volume: 306, Issue:6888

    Topics: Adult; Aspirin; Blood Pressure; Coronary Disease; Diabetes Mellitus; England; Humans; Hypercholester

1993
Optimal management of chronic leg ulcers in the elderly.
    Drugs & aging, 1997, Volume: 10, Issue:5

    Topics: Administration, Oral; Aged; Aging; Arterial Occlusive Diseases; Aspirin; Bandages; Combined Modality

1997
Aspirin therapy in diabetes.
    Diabetes care, 1997, Volume: 20, Issue:11

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans

1997
[Intervention in risk factors and protection of target organs].
    Anales de medicina interna (Madrid, Spain : 1984), 1997, Volume: 14, Issue:9

    Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est

1997
Risk factors for coronary heart disease in women.
    Cardiology clinics, 1998, Volume: 16, Issue:1

    Topics: Aged; Antioxidants; Aspirin; Cholesterol; Contraceptives, Oral; Coronary Disease; Diabetes Mellitus;

1998
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
    BMJ (Clinical research ed.), 1998, Apr-25, Volume: 316, Issue:7140

    Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet

1998
Managing the diabetic patient with acute myocardial infarction.
    Diabetic medicine : a journal of the British Diabetic Association, 1998, Volume: 15, Issue:4

    Topics: Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Humans; Myocardial Infarction; Ri

1998
How to improve the cardiac prognosis for diabetes.
    Diabetes care, 1999, Volume: 22 Suppl 2

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor

1999
Diabetes and myocardial infarction.
    Bailliere's best practice & research. Clinical endocrinology & metabolism, 1999, Volume: 13, Issue:2

    Topics: Adrenergic beta-Antagonists; Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Huma

1999
[Treatment of diabetic patients with ischaemic heart disease].
    Ugeskrift for laeger, 2000, Jul-31, Volume: 162, Issue:31

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio

2000
Other drug treatments: the evidence.
    The Proceedings of the Nutrition Society, 2000, Volume: 59, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspi

2000
[Platelet aggregation inhibitors in diabetes mellitus].
    Acta medica Austriaca, 1999, Volume: 26, Issue:5

    Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggregation; Platelet Aggregatio

1999
Treatment for the procoagulant state in type 2 diabetes.
    Endocrinology and metabolism clinics of North America, 2001, Volume: 30, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Disorders; Blood Platelets; Diab

2001
[Acetylsalicylic acid in primary prevention of cardiovascular events; literature study].
    Nederlands tijdschrift voor geneeskunde, 2002, Jan-12, Volume: 146, Issue:2

    Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Hyperlipidemias; Hype

2002
Cardiovascular risk reduction in renal transplantation. Strategies for success.
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2002, Volume: 54, Issue:2

    Topics: Arteriosclerosis; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Cost-Benefit

2002
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
    Haemostasis, 1986, Volume: 16, Issue:6

    Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic;

1986
Insulin and arachidonic acid metabolism in diabetes mellitus.
    Metabolism: clinical and experimental, 1985, Volume: 34, Issue:12 Suppl 1

    Topics: Animals; Arachidonic Acid; Arachidonic Acids; Arthritis, Rheumatoid; Aspirin; Blood Platelets; Diabe

1985

Trials

62 trials available for aspirin and Diabetes Mellitus

ArticleYear
Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
    JAMA network open, 2021, 12-01, Volume: 4, Issue:12

    Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Fatty Acids, Omega-3; Female; H

2021
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
    European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-29, Volume: 8, Issue:7

    Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe

2022
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
    European heart journal, 2022, 06-01, Volume: 43, Issue:21

    Topics: Aspirin; Cognition; Cognitive Dysfunction; Dementia; Diabetes Mellitus; Humans

2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
    Journal of thrombosis and thrombolysis, 2022, Volume: 54, Issue:3

    Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Di

2022
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
    American heart journal, 2023, Volume: 256

    Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Perc

2023
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial.
    Trials, 2023, Mar-04, Volume: 24, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Thromboxane B2

2023
Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
    JAMA cardiology, 2023, 06-01, Volume: 8, Issue:6

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male

2023
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
    Heart (British Cardiac Society), 2023, 09-13, Volume: 109, Issue:19

    Topics: Aspirin; Diabetes Mellitus; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Reproduc

2023
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199

    Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressur

2019
Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients.
    Journal of cardiology, 2020, Volume: 75, Issue:4

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Fibrinolytic Agents; Humans; Inci

2020
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    JACC. Cardiovascular interventions, 2019, 12-09, Volume: 12, Issue:23

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido

2019
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial.
    Circulation, 2020, 06-09, Volume: 141, Issue:23

    Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Drug

2020
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Journal of the American College of Cardiology, 2020, 05-19, Volume: 75, Issue:19

    Topics: Aspirin; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Hemorrhage; Humans; Perc

2020
ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.
    European journal of clinical pharmacology, 2021, Volume: 77, Issue:4

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Administra

2021
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Budgets; Cardiovascular Diseases; Ci

2021
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    JAMA cardiology, 2021, 01-01, Volume: 6, Issue:1

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double

2021
Current-Induced Vasodilation Specifically Detects, and Correlates With the Time Since, Last Aspirin Intake: An Interventional Study of 830 Patients.
    Journal of cardiovascular pharmacology and therapeutics, 2021, Volume: 26, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Diabetes Mellitus; Female; Heart Dis

2021
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation.
    Journal of cardiovascular pharmacology, 2021, 09-01, Volume: 78, Issue:3

    Topics: Aged; Aged, 80 and over; Anemia; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Comor

2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
    Journal of the American College of Cardiology, 2021, 07-06, Volume: 78, Issue:1

    Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Factor Xa Inhi

2021
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
    American heart journal, 2017, Volume: 188

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus; Dose-Response Relationship,

2017
ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    American heart journal, 2018, Volume: 198

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Ad

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus

2018
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su

2018
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su

2018
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su

2018
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    The New England journal of medicine, 2018, 10-18, Volume: 379, Issue:16

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su

2018
A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study.
    Journal of proteomics, 2019, 02-10, Volume: 192

    Topics: Acetylation; Adult; Aspirin; Blood Glucose; Blood Platelets; Cyclooxygenase 1; Diabetes Mellitus; Fe

2019
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:3

    Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem

2019
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery D

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Journal of the American College of Cardiology, 2014, Feb-04, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    JAMA, 2014, Dec-17, Volume: 312, Issue:23

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D

2014
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
    Contemporary clinical trials, 2015, Volume: 43

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co

2015
Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial.
    Implementation science : IS, 2015, Jun-10, Volume: 10

    Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; C

2015
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study.
    Circulation, 2016, May-03, Volume: 133, Issue:18

    Topics: Aged; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Ma

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    JAMA, 2016, Apr-26, Volume: 315, Issue:16

    Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent

2016
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
    Stroke, 2016, Volume: 47, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem

2016
Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
    Trials, 2016, 06-13, Volume: 17, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Consent Forms; Cost-Benefit Analysis; Diabetes Mellitus; Dietary S

2016
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona

2017
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
    American heart journal, 2010, Volume: 159, Issue:3

    Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cohort Studies; Diabetes Mellitus; Dose-Response Rel

2010
Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes.
    International journal of hematology, 2010, Volume: 92, Issue:2

    Topics: Adult; Aged; Aspirin; Blood Platelets; Chemoprevention; Coronary Artery Disease; Diabetes Mellitus;

2010
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:2

    Topics: Aged; Aspirin; Blood Platelets; Chemotherapy, Adjuvant; Cilostazol; Clopidogrel; Cross-Over Studies;

2011
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Cholesterol, LDL; Cilostazol; Diabetes Mellitus; Endothelium, Vascula

2011
Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:11

    Topics: Aged; Aspirin; Blood Platelets; Diabetes Mellitus; Female; Genotype; Humans; Male; Middle Aged; Muta

2011
Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study.
    Thrombosis research, 2012, Volume: 129, Issue:6

    Topics: Aspirin; Blood Platelets; Case-Control Studies; Diabetes Mellitus; Drug Synergism; Female; Humans; H

2012
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6

    Topics: Aged; Antihypertensive Agents; Aspirin; Black or African American; Blood Pressure; Chi-Square Distri

2013
Cardiovascular therapy, diagnostic procedures, and control of risk factors in patients with diabetes or coronary artery disease in Poland: the Kardia‑Pol registry.
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Female; H

2012
Randomized controlled trial of symptomatic middle cerebral artery stenosis: endovascular versus medical therapy in a Chinese population.
    Stroke, 2012, Volume: 43, Issue:12

    Topics: Adult; Aged; Angioplasty; Asian People; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combi

2012
Assessment of the Siksika chronic disease nephropathy-prevention clinic.
    Canadian family physician Medecin de famille canadien, 2013, Volume: 59, Issue:1

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bl

2013
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
    The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi

2002
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
    The American journal of cardiology, 2002, Oct-01, Volume: 90, Issue:7

    Topics: Age Factors; Aged; Aspirin; Clopidogrel; Creatinine; Diabetes Mellitus; Female; Humans; Male; Massac

2002
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Patient-directed intervention versus clinician reminders alone to improve aspirin use in diabetes: a cluster randomized trial.
    Joint Commission journal on quality and patient safety, 2008, Volume: 34, Issue:2

    Topics: Aged; Aspirin; Diabetes Mellitus; Evidence-Based Medicine; Female; Humans; Interviews as Topic; Male

2008
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
    Journal of the American College of Cardiology, 2008, Mar-25, Volume: 51, Issue:12

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest

2008
Blockade of chlorpropamide alcohol flush by aspirin.
    Lancet (London, England), 1980, Feb-23, Volume: 1, Issue:8165

    Topics: Aspirin; Blood Vessels; Body Temperature; Chlorpheniramine; Chlorpropamide; Cimetidine; Diabetes Mel

1980
Study to begin on whether aspirin can delay senile cataract formation.
    JAMA, 1980, Dec-12, Volume: 244, Issue:23

    Topics: Aged; Aspirin; Cataract; Clinical Trials as Topic; Diabetes Mellitus; Dose-Response Relationship, Dr

1980
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.
    Blood pressure, 1994, Volume: 3, Issue:5

    Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Angiotensin-Converting Enzym

1994
C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.
    Annals of epidemiology, 1993, Volume: 3, Issue:1

    Topics: Adult; Aspirin; C-Peptide; Combined Modality Therapy; Diabetes Mellitus; Diabetic Retinopathy; Discr

1993
Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1996, Volume: 114, Issue:9

    Topics: Adult; Anti-Inflammatory Agents; Aspirin; Blood-Retinal Barrier; Capillary Permeability; Diabetes Co

1996
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
    Circulation, 1998, Feb-10, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In

1998
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Circulation, 1999, May-11, Volume: 99, Issue:18

    Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh

1999
Alcohol consumption and risk of coronary heart disease by diabetes status.
    Circulation, 2000, Aug-01, Volume: 102, Issue:5

    Topics: Alcohol Drinking; Aspirin; beta Carotene; Cardiovascular Diseases; Coronary Disease; Diabetes Mellit

2000
Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects.
    Diabetes, 1978, Volume: 27, Issue:12

    Topics: Adult; Aged; Aspirin; Blood Glucose; Diabetes Mellitus; Glucagon; Glucose; Humans; Ibuprofen; Insuli

1978
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.
    JAMA, 1992, Sep-09, Volume: 268, Issue:10

    Topics: Adolescent; Adult; Aged; Aspirin; Cerebrovascular Disorders; Diabetes Mellitus; Diabetic Retinopathy

1992
European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke.
    Stroke, 1992, Volume: 23, Issue:6

    Topics: Aged; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Dipyridamole; D

1992
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
    Haemostasis, 1986, Volume: 16, Issue:6

    Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic;

1986

Other Studies

291 other studies available for aspirin and Diabetes Mellitus

ArticleYear
Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents.
    Bioorganic & medicinal chemistry letters, 2009, Mar-15, Volume: 19, Issue:6

    Topics: Adipocytes; Animals; Benzenesulfonamides; Biological Transport; Chemistry, Pharmaceutical; Diabetes

2009
Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic.
    Irish journal of medical science, 2022, Volume: 191, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; COVID-19; Diabetes Mellitus; Humans; Pandemics; Platelet Aggregati

2022
The comparison between the effects of aspirin and clopidogrel monotherapy on postoperative bleeding in diabetic patients after off-pump coronary artery bypass surgery.
    Reviews in cardiovascular medicine, 2021, Sep-24, Volume: 22, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Diabetes Mellitus; Humans; Platelet Aggregat

2021
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
    Stroke, 2022, Volume: 53, Issue:2

    Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45

2022
Associations between aspirin prophylaxis and fetal growth and preeclampsia in women with pregestational diabetes.
    The Australian & New Zealand journal of obstetrics & gynaecology, 2022, Volume: 62, Issue:2

    Topics: Analgesics; Aspirin; Diabetes Mellitus; Female; Fetal Development; Humans; Pre-Eclampsia; Pregnancy;

2022
Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status.
    The American journal of cardiology, 2022, 05-15, Volume: 171

    Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Percutaneous Coronary Intervention; Pla

2022
The end of aspirin for dementia prevention in diabetes?
    European heart journal, 2022, 06-01, Volume: 43, Issue:21

    Topics: Aspirin; Cardiovascular Diseases; Cognition; Dementia; Diabetes Mellitus; Humans; Platelet Aggregati

2022
Trends and Determinants of Self-reported Aspirin Use Among Patients With Diabetes Stratified by Presence and Risk of Cardiovascular Diseases: A Repeated Pan-Canadian Cross-sectional Study.
    Canadian journal of diabetes, 2022, Volume: 46, Issue:4

    Topics: Aspirin; Canada; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Humans; Platel

2022
The Association between Glycosylated Hemoglobin Level and Platelets Reactivity in Patients with Diabetes Mellitus Undergoing Elective Coronary Artery Bypass Grafting.
    The Thoracic and cardiovascular surgeon, 2023, Volume: 71, Issue:6

    Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Artery Bypass; Diabetes Mellitus; Glycated

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Association between first-step analgesic use and cancer in patients with diabetes.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:2

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Female; Humans; Mal

2023
Aspirin Suppresses Hepatic Glucagon Signaling Through Decreasing Production of Thromboxane A2.
    Endocrinology, 2023, 01-09, Volume: 164, Issue:3

    Topics: Aspirin; Diabetes Mellitus; Glucagon; Gluconeogenesis; Glucose; Humans; Hyperglycemia; Hypoglycemic

2023
Aspirin and Risk of Specific Breast Cancer Subtype in Women with Diabetes.
    Journal of women's health (2002), 2023, Volume: 32, Issue:3

    Topics: Aspirin; Breast Neoplasms; Diabetes Mellitus; Female; Hormones; Humans; Middle Aged; Retrospective S

2023
Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort.
    Journal of endocrinological investigation, 2023, Volume: 46, Issue:7

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Male; Retrospective Studi

2023
Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus.
    American journal of obstetrics & gynecology MFM, 2023, Volume: 5, Issue:4

    Topics: Aspirin; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension, Pregnancy-Induced

2023
Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes.
    European journal of preventive cardiology, 2023, 09-06, Volume: 30, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Europe; Female;

2023
Low-dose aspirin therapy for primary prevention of cardiovascular disease: where are we at?
    European journal of preventive cardiology, 2023, 09-06, Volume: 30, Issue:12

    Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors;

2023
Prediabetes, diabetes and loss of disability-free survival in a community-based older cohort: a post-hoc analysis of the ASPirin in Reducing Events in the Elderly trial.
    Age and ageing, 2023, 04-01, Volume: 52, Issue:4

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Prediabetic State; Prognosis

2023
The Diabetic Platelets.
    JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73, Issue:5

    Topics: Aspirin; Blood Platelets; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Humans; Platelet Ag

2023
Mortality in Patients Hospitalized With Acute Myocardial Infarction Without Standard Modifiable Risk Factors: The ARIC Study Community Surveillance.
    Journal of the American Heart Association, 2023, 07-04, Volume: 12, Issue:13

    Topics: Aspirin; Diabetes Mellitus; Hospitalization; Humans; Myocardial Infarction; Prognosis; Risk Factors

2023
Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study.
    World journal of urology, 2023, Volume: 41, Issue:12

    Topics: Adult; Aged; Aspirin; Cross-Sectional Studies; Diabetes Mellitus; Humans; Hypertension; Kidney Calcu

2023
Risks May Outweigh Benefits Of Aspirin Use in Diabetes.
    The American journal of nursing, 2019, Volume: 119, Issue:9

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Risk F

2019
Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.
    British journal of cancer, 2019, Volume: 121, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Fe

2019
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosen
    European heart journal, 2019, Oct-14, Volume: 40, Issue:39

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Cholesterol,

2019
Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
    Journal of cardiovascular translational research, 2020, Volume: 13, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Re

2020
Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy.
    Cardiovascular revascularization medicine : including molecular interventions, 2020, Volume: 21, Issue:9

    Topics: Adenosine; Aftercare; Aspirin; Blood Platelets; Diabetes Mellitus; Drug Therapy, Combination; Female

2020
Aspirin for primary prevention of cardiovascular disease in women.
    Menopause (New York, N.Y.), 2020, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Hemorrh

2020
Twilight, the Dawn of a New Era of Aspirin-Free PCI?
    Journal of the American College of Cardiology, 2020, 05-19, Volume: 75, Issue:19

    Topics: Aspirin; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibit

2020
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.
    European heart journal. Cardiovascular pharmacotherapy, 2021, 11-03, Volume: 7, Issue:6

    Topics: Aspirin; Brain Ischemia; Coronary Artery Disease; Diabetes Mellitus; Humans; Percutaneous Coronary I

2021
Potential drug-drug interactions in ICU patients: a retrospective study.
    Drug metabolism and personalized therapy, 2020, 07-20, Volume: 35, Issue:3

    Topics: Aspirin; Diabetes Mellitus; Drug Interactions; Enoxaparin; Hospitalization; Humans; Hypertension; In

2020
Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease.
    Annali italiani di chirurgia, 2020, Volume: 91

    Topics: Aspirin; Cilostazol; Diabetes Mellitus; Diabetic Foot; Humans; Peripheral Arterial Disease; Retrospe

2020
P2Y
    Journal of the American College of Cardiology, 2020, 09-08, Volume: 76, Issue:10

    Topics: Aspirin; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Anta

2020
Reply: P2Y
    Journal of the American College of Cardiology, 2020, 09-08, Volume: 76, Issue:10

    Topics: Aspirin; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Anta

2020
The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:1

    Topics: Aspirin; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms;

2021
Co-morbid risk factors and NSAID use among white and black Americans that predicts overall survival from diagnosed colon cancer.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African American; Cohort Studies;

2020
The impact of patient-centered medical home certification on quality of care for patients with diabetes.
    Health services research, 2021, Volume: 56, Issue:3

    Topics: Age Factors; Aged; Aspirin; Blood Pressure; Certification; Cholesterol; Diabetes Mellitus; Electroni

2021
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
    The American journal of cardiology, 2021, 03-01, Volume: 142

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual

2021
Impact of Preoperative Aspirin on Long-Term Outcomes in Diabetic Patients Following Coronary Artery Bypass Grafting: a Propensity Score Matched Study.
    Brazilian journal of cardiovascular surgery, 2020, 12-01, Volume: 35, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; D

2020
The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection.
    The FEBS journal, 2021, Volume: 288, Issue:17

    Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus;

2021
Aspirin and pre-eclampsia prevention in women with pre-existing diabetes: a retrospective study.
    Internal medicine journal, 2021, Volume: 51, Issue:10

    Topics: Aspirin; Diabetes Mellitus; Female; Humans; Placenta; Pre-Eclampsia; Pregnancy; Retrospective Studie

2021
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
    The American journal of cardiology, 2021, 06-01, Volume: 148

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete

2021
Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
    Journal of medical virology, 2021, Volume: 93, Issue:9

    Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Antiviral Agents; Aspirin; Blood Platelets; Coronary

2021
Benefits of Ticagrelor Plus Aspirin According to Diabetes-Related Factors: A Complex Equation.
    Journal of the American College of Cardiology, 2021, 05-18, Volume: 77, Issue:19

    Topics: Aspirin; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagon

2021
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 08-11, Volume: 8, Issue:5

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Denmark;

2022
Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
    Clinical and experimental nephrology, 2021, Volume: 25, Issue:10

    Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal

2021
Daily Low-Dose Aspirin, Diabetes, and Age-Still Looking for a Balance.
    JAMA network open, 2021, 06-01, Volume: 4, Issue:6

    Topics: Aspirin; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors

2021
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabet

2021
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
    JACC. Cardiovascular interventions, 2017, 04-10, Volume: 10, Issue:7

    Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Administration

2017
Recommendations on the Clinical Use of Compound Danshen Dripping Pills.
    Chinese medical journal, 2017, Apr-20, Volume: 130, Issue:8

    Topics: Angina Pectoris; Aspirin; Camphanes; Clopidogrel; Coronary Disease; Diabetes Mellitus; Diabetic Neph

2017
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
    Circulation, 2017, 05-02, Volume: 135, Issue:18

    Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infa

2017
Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan.
    Journal of women's health (2002), 2017, Volume: 26, Issue:12

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cardiovascular Dise

2017
Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment.
    Diabetes care, 2017, Volume: 40, Issue:8

    Topics: Aged; Aspirin; Cohort Studies; Comorbidity; Coronary Angiography; Coronary Artery Disease; Denmark;

2017
Relevance of Indications for CABG in Evaluating the Effect of Dual Antiplatelet Therapy.
    Journal of the American College of Cardiology, 2017, 07-25, Volume: 70, Issue:4

    Topics: Aspirin; Coronary Artery Bypass; Diabetes Mellitus; Freedom; Humans; Platelet Aggregation Inhibitors

2017
MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.
    BioMed research international, 2017, Volume: 2017

    Topics: Aspirin; Blood Platelets; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Male; Matrix M

2017
Associations of Statins and Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma.
    The Journal of investigative dermatology, 2017, Volume: 137, Issue:12

    Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectio

2017
Does Aspirin Decrease Risk of Specific Breast Cancer Subtype in Women with Diabetes?
    Journal of women's health (2002), 2017, Volume: 26, Issue:12

    Topics: Aspirin; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Risk; Risk Factors

2017
False increase of glycated hemoglobin due to aspirin interference in Tosoh G8 analyzer.
    Clinical chemistry and laboratory medicine, 2018, 04-25, Volume: 56, Issue:5

    Topics: Aspirin; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitus; False Positive Reac

2018
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Annals of internal medicine, 2018, 05-01, Volume: 168, Issue:9

    Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure Monitoring, Ambulatory; Coronary Disease; Di

2018
Aspirin for primary prevention of CVD: a matter of balance.
    Nature reviews. Cardiology, 2018, Volume: 15, Issue:11

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention

2018
Primary vascular prevention: The end of the road for aspirin?
    Diabetes & vascular disease research, 2018, Volume: 15, Issue:6

    Topics: Aspirin; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies; Evidence-Based Medicine

2018
Aspirin for primary prevention of cardiovascular disease events in diabetes: the balancing act?
    The journal of the Royal College of Physicians of Edinburgh, 2018, Volume: 48, Issue:4

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention

2018
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
    Annals of internal medicine, 2018, 12-18, Volume: 169, Issue:12

    Topics: Aspirin; Diabetes Mellitus; Hemorrhage; Humans; Primary Prevention

2018
Aspirin for primary prevention of cardiovascular disease in diabetes.
    Journal of diabetes investigation, 2019, Volume: 10, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans

2019
What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
    Cardiovascular research, 2019, 02-01, Volume: 115, Issue:2

    Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus

2019
Aspirin in people with diabetes: Time to clean up the prescription list?
    Diabetes research and clinical practice, 2019, Volume: 149

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Prevention; Risk Assessment

2019
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer.
    JAMA network open, 2019, 03-01, Volume: 2, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis

2019
Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs.
    Journal of community health, 2019, Volume: 44, Issue:3

    Topics: Aged; Aspirin; Black or African American; Cardiovascular Diseases; Diabetes Mellitus; Female; Health

2019
A precision medicine approach for the primary prevention of cardiovascular events in diabetic patients.
    European journal of preventive cardiology, 2019, Volume: 26, Issue:16

    Topics: Aspirin; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Humans; Precision Medici

2019
Do Statins Have a Positive Impact on Patients with Coronary Microvascular Dysfunction on Long-Term Clinical Outcome? A Large Retrospective Cohort Study.
    BioMed research international, 2019, Volume: 2019

    Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Related Side E

2019
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
    Journal of hypertension, 2019, Volume: 37, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha

2019
Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Journal of thrombosis and thrombolysis, 2019, Volume: 48, Issue:3

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Diabetes

2019
Secondary prevention advices after cardiovascular index event: From drug prescription to risk factors control in real world practice.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2019, 05-20, Volume: 89, Issue:2

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure; Cardiovascular Diseases;

2019
Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Comorbidity; Cross-Se

2019
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
    Vascular pharmacology, 2019, Volume: 120

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Diabetes Mellitu

2019
Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes.
    Diabetes, 2013, Volume: 62, Issue:3

    Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Abnormalities; Diabetes

2013
Evidenced-based antithrombotic therapy for acute coronary syndromes.
    Diabetes, 2013, Volume: 62, Issue:3

    Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Drug Labeling; Human

2013
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.
    Clinical cardiology, 2013, Volume: 36, Issue:4

    Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Angiotensin Receptor Antagonists; Aspirin; Card

2013
Intracranial hemorrhages related with warfarin use and comparison of warfarin and acetylsalicylic acid.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation;

2014
Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts.
    Journal of gastroenterology, 2014, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulant

2014
Antihyperglycemic and antinociceptive activity evaluation of 'khoyer' prepared from boiling the wood of Acacia catechu in water.
    African journal of traditional, complementary, and alternative medicines : AJTCAM, 2013, Volume: 10, Issue:4

    Topics: Acacia; Acetic Acid; Analgesics; Animals; Aspirin; Bangladesh; Behavior, Animal; Blood Glucose; Diab

2013
Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers.
    BMC research notes, 2013, Nov-12, Volume: 6

    Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Asian People; Aspirin; Diabetes Complications; Diabetes

2013
Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction.
    Diabetes & vascular disease research, 2014, Volume: 11, Issue:3

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver

2014
Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabete

2014
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:5

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor

2014
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
    World journal of urology, 2015, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascula

2015
Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study.
    Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:3

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms;

2015
Assessing Diabetes Care Disparities with Ambulatory Care Quality Measures.
    Health services research, 2015, Volume: 50, Issue:4

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Aspirin; Cholesterol, LDL; Diabetes Mellitus; Electronic H

2015
Association between low-dose aspirin and periodontal disease: results from the continuous national health and nutrition examination survey (NHANES) 2011-2012.
    Journal of clinical periodontology, 2015, Volume: 42, Issue:4

    Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Diabe

2015
Aspirin Has a Protective Effect Against Adverse Outcomes in Patients with Nonvariceal Upper Gastrointestinal Bleeding.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:7

    Topics: Adult; Aged; Aging; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Fibrinolytic Agents

2015
Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
    American heart journal, 2015, Volume: 170, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidemias; Female; Guideline Adherenc

2015
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
    British journal of cancer, 2015, Jul-28, Volume: 113, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; F

2015
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Atherosclerosis, 2015, Volume: 242, Issue:1

    Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-4

2015
Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Dia

2016
Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.
    Preventing chronic disease, 2015, Nov-19, Volume: 12

    Topics: Aged; Aspirin; Behavioral Risk Factor Surveillance System; Diabetes Mellitus; Humans; Hypercholester

2015
Aspirin in the prevention of cardiovascular events in patients with diabetes.
    Postgraduate medicine, 2016, Volume: 128, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Admin

2016
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
    Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combinati

2016
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
    Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:5

    Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combinati

2016
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
    Journal of the American College of Cardiology, 2016, May-17, Volume: 67, Issue:19

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St

2016
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
    Thrombosis research, 2016, Volume: 143

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Glucose; Blood Platelets; Diabetes Complica

2016
    Arquivos brasileiros de cardiologia, 2014, Volume: 102, Issue:5 Suppl 1

    Topics: Aspirin; Atherosclerosis; Brazil; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitu

2014
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.
    Obstetrics and gynecology, 2016, Volume: 128, Issue:1

    Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Diabetes Mellit

2016
Effects of low-dose aspirin in subjects with dyslipidemia.
    Lipids in health and disease, 2016, Jun-16, Volume: 15

    Topics: Adult; Aspirin; C-Reactive Protein; Cholesterol, LDL; Convalescence; Coronary Angiography; Coronary

2016
Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients.
    BMC nephrology, 2016, 07-26, Volume: 17

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arabs; Aspirin; Calcium Carbonate; Comorbidity; Diabetes

2016
Combined aspirin and anticoagulant therapy in patients with atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:1

    Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Diseas

2017
In vitro glycation of bovine liver catalase by glucose and fructose and antigycation effects of aspirin: a spectroscopic study.
    Journal of biomolecular structure & dynamics, 2017, Volume: 35, Issue:14

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Catalase; Cattle; Diabetes Mellitus; Fruc

2017
Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus.
    Circulation, 2016, Nov-15, Volume: 134, Issue:20

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Risk Factors

2016
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    The American journal of cardiology, 2016, Dec-15, Volume: 118, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I

2016
Optimal duration of dual antiplatelet therapy after stent implantation in patients with or without diabetes.
    BMJ (Clinical research ed.), 2016, 11-03, Volume: 355

    Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggrega

2016
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo.
    Annals of internal medicine, 2016, 11-15, Volume: 165, Issue:10

    Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors

2016
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    American heart journal, 2016, Volume: 182

    Topics: Aged; Aspirin; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; D

2016
Adding CABG to the Dual Antiplatelet Salad.
    Journal of the American College of Cardiology, 2017, 01-17, Volume: 69, Issue:2

    Topics: Aspirin; Coronary Artery Bypass; Diabetes Mellitus; Freedom; Humans; Platelet Aggregation Inhibitors

2017
Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.
    The American journal of cardiology, 2017, Apr-15, Volume: 119, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Coronary Artery Disease; Diabetes Mellitus;

2017
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:1

    Topics: Aged; Aspirin; Baltimore; Biomarkers; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Femal

2008
Biochemical evaluation of the antiplatelet effect of aspirin in patients at different levels of cardiovascular risk.
    Bratislavske lekarske listy, 2008, Volume: 109, Issue:4

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Female

2008
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
    Nature clinical practice. Cardiovascular medicine, 2009, Volume: 6, Issue:3

    Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Pe

2009
[Factors that influence the implementation of the guidelines for aspirin use by diabetic patients in Israel].
    Harefuah, 2008, Volume: 147, Issue:12

    Topics: Adult; Aspirin; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Female; Guidelines

2008
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
    The American journal of cardiology, 2009, Nov-01, Volume: 104, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri

2009
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar

2010
[Diabetes and a low dose of aspirin].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:11

    Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans

2009
Another look at the results of the JUPITER trial.
    The American journal of cardiology, 2009, Dec-01, Volume: 104, Issue:11

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Mass Index; C-Reactive Prot

2009
Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction.
    Clinical cardiology, 2009, Volume: 32, Issue:12

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bundle-Branch Block; Coumarins; Diabetes Mellitus; Femal

2009
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
    Journal of the American College of Cardiology, 2010, Feb-16, Volume: 55, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary

2010
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Journal of the American College of Cardiology, 2010, Mar-16, Volume: 55, Issue:11

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe

2010
[Evaluation and improvement in the prescribing of anti-platelet drugs in diabetic patients].
    Atencion primaria, 2011, Volume: 43, Issue:1

    Topics: Adult; Aspirin; Diabetes Mellitus; Drug Prescriptions; Female; Humans; Male; Platelet Aggregation In

2011
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College
    Diabetes care, 2010, Volume: 33, Issue:6

    Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Melli

2010
Aspirin use in elderly women receiving medication therapy management services.
    Advances in therapy, 2010, Volume: 27, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Comorbidity; Contraindications; Diabetes

2010
The effect of aspirin on atherogenic diet-induced diabetes mellitus.
    Basic & clinical pharmacology & toxicology, 2011, Volume: 108, Issue:6

    Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Cholestero

2011
Clinical data extraction and feedback in general practice: a case study from Australian primary care.
    Informatics in primary care, 2010, Volume: 18, Issue:3

    Topics: Aspirin; Australia; Coronary Disease; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hydroxymethylg

2010
Antiplatelet therapy for every diabetic person?
    Diabetes care, 2011, Volume: 34 Suppl 2

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Random

2011
Ischemic stroke in patients receiving aspirin.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis

2012
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
    The American journal of cardiology, 2011, Nov-01, Volume: 108, Issue:9

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri

2011
Aspirin for CV prevention -- for which patients?
    The Journal of family practice, 2011, Volume: 60, Issue:9

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Female; Fibrinolytic Age

2011
Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.
    The Journal of clinical investigation, 2011, Volume: 121, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Aspirin; Blood Glucose; Case-Control Studies; Co

2011
Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetes.
    Diabetes care, 2012, Volume: 35, Issue:3

    Topics: Adult; Aged; Aspirin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Female; Humans; Male;

2012
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
    Platelets, 2013, Volume: 24, Issue:2

    Topics: Adenosine Diphosphate; Aged; Alprostadil; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytoc

2013
The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease.
    The aging male : the official journal of the International Society for the Study of the Aging Male, 2012, Volume: 15, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Drug Resistance; Human

2012
Association of aspirin use with major bleeding in patients with and without diabetes.
    JAMA, 2012, Jun-06, Volume: 307, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studi

2012
Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice?
    JAMA, 2012, Jun-06, Volume: 307, Issue:21

    Topics: Aspirin; Diabetes Mellitus; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; M

2012
Diabetes: Does aspirin increase the risk of major bleeds?
    Nature reviews. Cardiology, 2012, Volume: 9, Issue:9

    Topics: Aspirin; Diabetes Mellitus; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment

2012
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Jun-01, Volume: 81, Issue:7

    Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor

2013
Benefits and risks of aspirin use.
    JAMA, 2012, Sep-19, Volume: 308, Issue:11

    Topics: Aspirin; Diabetes Mellitus; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; M

2012
Benefits and risks of aspirin use.
    JAMA, 2012, Sep-19, Volume: 308, Issue:11

    Topics: Aspirin; Diabetes Mellitus; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; M

2012
Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006.
    Journal of the Chinese Medical Association : JCMA, 2012, Volume: 75, Issue:11

    Topics: Adult; Aged; Aspirin; Coronary Disease; Diabetes Mellitus; Drug Utilization; Female; Humans; Hydroxy

2012
Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?
    Renal failure, 2013, Volume: 35, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E

2013
Pharmaceutical care for patients with acute myocardial infarction in Hungary.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:2

    Topics: Acute Disease; Adult; Aged; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Drug Therapy, Comb

2013
Unmet needs of diabetic patients.
    Journal of the Chinese Medical Association : JCMA, 2012, Volume: 75, Issue:12

    Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Health Services Needs and Dem

2012
Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease.
    American heart journal, 2002, Volume: 144, Issue:2

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis

2002
Aspirin therapy in diabetes.
    Diabetes care, 2003, Volume: 26 Suppl 1

    Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Meta-Analysis as Topic; Quality Assurance

2003
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils.
    European journal of clinical investigation, 2002, Volume: 32, Issue:12

    Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control S

2002
Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal anti-inflammatory drugs.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2003, Volume: 111, Issue:1

    Topics: Amyloid; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Circular Dichroism; Congo Red; Cyclooxyge

2003
Smoking and the risk of hemorrhagic stroke in men.
    Stroke, 2003, Volume: 34, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind

2003
Guidelines for improving the care of the older person with diabetes mellitus.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:5 Suppl Gu

    Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M

2003
Guidelines for improving the care of the older person with diabetes mellitus.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:5 Suppl Gu

    Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M

2003
Guidelines for improving the care of the older person with diabetes mellitus.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:5 Suppl Gu

    Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M

2003
Guidelines for improving the care of the older person with diabetes mellitus.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:5 Suppl Gu

    Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M

2003
Clopidogrel and percutaneous coronary interventions.
    JAMA, 2003, Apr-16, Volume: 289, Issue:15

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Administration Schedul

2003
[Use of anti-aggregant drugs in primary and secondary cardiovascular prevention in diabetics in town and country in the León area].
    Atencion primaria, 2003, Volume: 31, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Humans; Primary Health Care; Primary Prevention

2003
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:5

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Data Collection; Diabetes M

2003
Aspirin and diabetes mellitus.
    British medical journal, 1957, Nov-09, Volume: 2, Issue:5053

    Topics: Aspirin; Diabetes Mellitus; Humans; Medical Records; Rheumatic Diseases

1957
ASPIRIN and diabetes.
    Nutrition reviews, 1958, Volume: 16, Issue:6

    Topics: Aspirin; Diabetes Mellitus; Humans

1958
Dinitrophenol and diabetes mellitus: a comparison with salicylate.
    British medical journal, 1958, Sep-20, Volume: 2, Issue:5098

    Topics: Aspirin; Diabetes Mellitus; Dinitrophenols; Humans; Nitrophenols; Salicylates

1958
The insulin equivalence of salicylate.
    British medical journal, 1959, Apr-04, Volume: 1, Issue:5126

    Topics: Aspirin; Diabetes Mellitus; Humans; Insulin; Salicylates

1959
[Acetylsalicylic acid therapy of diabetes mellitus].
    Prensa medica argentina, 1958, Aug-29, Volume: 45, Issue:35

    Topics: Aspirin; Diabetes Mellitus; Humans

1958
Reappraisal of the hypoglycemic action of acetylsalicylate.
    Metabolism: clinical and experimental, 1959, Jul-01, Volume: 8, Issue:4 Pt 1

    Topics: Aspirin; Blood Glucose; Diabetes Mellitus; Humans; Hypoglycemic Agents

1959
[HYPOGLYCEMIC ACTION OF ACETYLSALICYLIC ACID IN DIABETES IN OLD AGE].
    Prensa medica argentina, 1963, Feb-15, Volume: 50

    Topics: Aspirin; Diabetes Mellitus; Geriatrics; Humans; Hypoglycemic Agents

1963
[ASPIRIN AND DIABETES. NEW FINDINGS ON THE BLOOD SUGAR DECREASING EFFECTS OF SALICYL PREPARATIONS].
    Medizinische Klinik, 1963, Oct-25, Volume: 58

    Topics: Aspirin; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; England; Humans; Pancreatic Dise

1963
A SIMPLIFIED VIEW OF FLUID THERAPY.
    Pediatric clinics of North America, 1964, Volume: 11

    Topics: Acidosis; Adrenal Insufficiency; Aspirin; Calcium; Child; Cystic Fibrosis; Dehydration; Diabetes Mel

1964
ACUTE RENAL FAILURE FOLLOWING ACETOPHENETIDIN INGESTION.
    The Journal of the Medical Society of New Jersey, 1964, Volume: 61

    Topics: Acidosis; Acute Kidney Injury; Aspirin; Caffeine; Diabetes Mellitus; Diabetic Ketoacidosis; Diagnosi

1964
LONG-TERM TREATMENT OF A PATIENT WITH RHEUMATOID ARTHRITIS.
    Physical therapy, 1964, Volume: 44

    Topics: Arthritis, Rheumatoid; Aspirin; Braces; Casts, Surgical; Contracture; Diabetes Mellitus; Drug Therap

1964
INHIBITION OF THE MOBILIZATION OF FREE FATTY ACIDS FROM ADIPOSE TISSUE IN DIABETES. II. EFFECT OF NICOTINIC ACID AND ACETYLSALICYLATE ON BLOOD GLUCOSE IN HUMAN DIABETICS.
    Acta medica Scandinavica, 1965, Volume: 178

    Topics: Adipose Tissue; Aspirin; Blood Glucose; Diabetes Mellitus; Fatty Acids; Fatty Acids, Nonesterified;

1965
Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.
    Circulation, 2003, Sep-23, Volume: 108, Issue:12

    Topics: Age Factors; Aspirin; C-Reactive Protein; Cholesterol; Diabetes Mellitus; Female; Heart Diseases; Hu

2003
Decisional attributes of patients with diabetes: the aspirin choice.
    Diabetes care, 2003, Volume: 26, Issue:10

    Topics: Adult; Aged; Aspirin; Attitude to Health; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes

2003
Aspirin therapy in diabetes.
    Diabetes care, 2004, Volume: 27 Suppl 1

    Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Male; Platelet Aggregation Inhibi

2004
[Acetylsalicylic acid consumption in patients with diabetes mellitus].
    Medicina clinica, 2004, Jan-31, Volume: 122, Issue:3

    Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; M

2004
[Underutilization of acetylsalicylic acid of cardiovascular prevention in patients with diabetes mellitus].
    Medicina clinica, 2004, Jan-31, Volume: 122, Issue:3

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega

2004
Effect of aspirin upon glycosuria of the partially depancreatized rat.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1950, Volume: 75, Issue:3

    Topics: Animals; Aspirin; Diabetes Mellitus; Glycosuria; Rats

1950
[Cardiovascular risk stratification in general practice].
    Zeitschrift fur Kardiologie, 2004, Volume: 93 Suppl 2

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; Cholesterol; Coronar

2004
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2003, Volume: 60, Issue:4

    Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov

2003
Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2004, Volume: 122, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Barbados; Black People; Cataract; Cohort Studies; Diabetes

2004
Aspirin resistance in diabetic patients.
    Diabetes care, 2004, Volume: 27, Issue:5

    Topics: Aspirin; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation

2004
Consensus statement for the prevention of vascular disease.
    Australian family physician, 2004, Volume: 33, Issue:4

    Topics: Aged; Aspirin; Atrial Fibrillation; Australia; Diabetes Complications; Diabetes Mellitus; Family Pra

2004
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
    Circulation, 2004, Jun-01, Volume: 109, Issue:21

    Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Cardiovascular Diseases; CD40 Ligand; Cohort Studies;

2004
Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study.
    American heart journal, 2004, Volume: 147, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin;

2004
[Aspirin use in patients with diabetes mellitus].
    Medicina clinica, 2004, Jul-10, Volume: 123, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; P

2004
[Aspirin use in patients with diabetes mellitus].
    Medicina clinica, 2004, Jul-10, Volume: 123, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans; Platelet Aggreg

2004
[Aspirin use in patients with diabetes mellitus].
    Medicina clinica, 2004, Jul-10, Volume: 123, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitu

2004
[Aspirin use in patients with diabetes mellitus].
    Medicina clinica, 2004, Jul-10, Volume: 123, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitu

2004
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999.
    Circulation, 2004, Sep-07, Volume: 110, Issue:10

    Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Agents; China; Coronary Disease; Devel

2004
Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey.
    Diabetes & metabolism, 2004, Volume: 30, Issue:4

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihyperte

2004
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    Neurology, 2005, Jan-25, Volume: 64, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant

2005
Cardiovascular risk in patients with type 2 diabetes.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Apr-26, Volume: 172, Issue:9

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca

2005
[Prophylaxis of stroke].
    Praxis, 2005, Jul-27, Volume: 94, Issue:30-31

    Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi

2005
Aspirin prophylaxis in diabetes mellitus.
    Family medicine, 2005, Volume: 37, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Humans; Treatment Outcome

2005
Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability.
    International psychogeriatrics, 2005, Volume: 17, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Brain; Dementia, Va

2005
A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors.
    Platelets, 2006, Volume: 17, Issue:1

    Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Diet; Drug Resistance; Female; Humans; Male; Mi

2006
Is aspirin effective in diabetic patients? Yes.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:12

    Topics: Aspirin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Treatment Outcome

2005
Is aspirin effective in diabetic patients? No.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:12

    Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Hemorrhage; Humans; Risk Assessment; Treatment F

2005
Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    The American journal of cardiology, 2006, Jan-01, Volume: 97, Issue:1

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Collagen Type I;

2006
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
    Thrombosis and haemostasis, 2006, Volume: 95, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease; Cyclooxygenase 1

2006
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
    Diabetes, 2006, Volume: 55, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema

2006
[Postoperative antithrombotic treatment in diabetic patients].
    Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95 Suppl 1

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mell

2006
Increased cardiovascular risk associated with diabetes in Dallas County.
    American heart journal, 2006, Volume: 151, Issue:5

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Calcium; Cardiovascular Dis

2006
Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus.
    Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 114, Issue:3

    Topics: Adult; Aspirin; Cardiovascular Diseases; Causality; Comorbidity; Diabetes Complications; Diabetes Me

2005
Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin.
    Thrombosis research, 2007, Volume: 119, Issue:4

    Topics: Adiponectin; Adult; Aspirin; Blood Platelets; Diabetes Mellitus; Drug Resistance; Humans; In Vitro T

2007
Evaluation of the uses of aspirin, statins and ACEIs/ARBs in a diabetes outpatient population in southern Thailand.
    Journal of evaluation in clinical practice, 2007, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cross-Sectional S

2007
Iron status and the use of non-steroidal anti-inflammatory drugs in hemodialysis patients.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2007, Volume: 11, Issue:3

    Topics: Aged; Anemia, Iron-Deficiency; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus;

2007
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Circulation, 2007, Jun-26, Volume: 115, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi

2007
Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain.
    BMC family practice, 2007, Oct-17, Volume: 8

    Topics: Aged; Ambulatory Care; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Follow-Up Studie

2007
Health issues in the Arab American community. The use of glucose-lowering agents and aspirin among Arab Americans with diabetes.
    Ethnicity & disease, 2007,Summer, Volume: 17, Issue:2 Suppl 3

    Topics: Aged; Arabs; Aspirin; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Int

2007
4 ways to save your heart.
    Diabetes forecast, 2008, Volume: 61, Issue:2

    Topics: Aspirin; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Angiopathies; Heart; Humans; Lip

2008
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
    Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin;

2008
[Behavior of alpha-ketoacids after certain hypoglycemic agents].
    Polskie Archiwum Medycyny Wewnetrznej, 1967, Volume: 39, Issue:2

    Topics: Animals; Aspirin; Biguanides; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Keto

1967
Acetylsalicyclic acid in diabetes.
    Lancet (London, England), 1981, Mar-07, Volume: 1, Issue:8219

    Topics: Aspirin; Diabetes Mellitus; Humans; Insulin; Insulin Secretion; Lysine; Prostaglandins E

1981
Secondary prevention of coronary heart disease.
    Acta cardiologica, 1984, Volume: 39, Issue:4

    Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B

1984
Treatment of canine spontaneous diabetes mellitus with aspirin.
    Metabolic and pediatric ophthalmology, 1980, Volume: 4, Issue:3

    Topics: Animals; Aspirin; Cyclic AMP; Cyclic GMP; Diabetes Mellitus; Diabetic Retinopathy; Disease Models, A

1980
Maturity-onset diabetes mellitus--toward a physiological appropriate management.
    Medical hypotheses, 1981, Volume: 7, Issue:10

    Topics: Amino Acids; Aspirin; Carnitine; Chromium; Diabetes Mellitus; Dietary Fats; Dietary Fiber; Fasting;

1981
Aspirin and prostacyclin treatment of diabetic dogs.
    Metabolic, pediatric, and systemic ophthalmology, 1983, Volume: 7, Issue:3

    Topics: Animals; Aspirin; Cyclic AMP; Diabetes Mellitus; Diabetic Retinopathy; Dog Diseases; Dogs; Epoproste

1983
Increased secretion of insulin but unchanged secretion of growth hormone in hyperglycaemic type II diabetics treated with acetyl-salicylic acid.
    Clinical endocrinology, 1983, Volume: 18, Issue:6

    Topics: Aged; Arginine; Aspirin; Blood Glucose; Diabetes Mellitus; Growth Hormone; Humans; Insulin; Insulin

1983
[Treatment of diabetes by oral administration of hypoglycemic agents].
    Zhonghua yi xue za zhi, 1984, Volume: 64, Issue:3

    Topics: Administration, Oral; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Ag

1984
Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions.
    Prostaglandins, 1984, Volume: 27, Issue:4

    Topics: Acetaminophen; Adult; Amino Acid Metabolism, Inborn Errors; Aspirin; Circadian Rhythm; Diabetes Mell

1984
[Effect of the single administration of acetylsalicylic acid and dipyridamole on microcirculation in patients with diabetes mellitus].
    Vrachebnoe delo, 1983, Issue:8

    Topics: Adolescent; Adult; Aged; Aspirin; Diabetes Mellitus; Dipyridamole; Female; Humans; Male; Microcircul

1983
Enhanced in vivo platelet activation in diabetes mellitus.
    Scandinavian journal of haematology, 1982, Volume: 29, Issue:2

    Topics: Adult; Aged; Aging; Aspirin; Blood Platelets; Calcium Channel Blockers; Cardiovascular Diseases; Dia

1982
Platelet adhesion to collagen in normal and von Willebrand's disease subjects.
    Thrombosis research, 1980, Mar-01, Volume: 17, Issue:5

    Topics: Animals; Aspirin; Blood Platelets; Collagen; Diabetes Mellitus; Dipyridamole; Factor VIII; Humans; K

1980
Impaired insulin secretion in human diabetes mellitus. II. A possible role for prostaglandins.
    Prostaglandins and medicine, 1981, Volume: 6, Issue:1

    Topics: Adult; Arginine; Aspirin; Blood Glucose; Diabetes Mellitus; Female; Glucose; Humans; Insulin; Insuli

1981
Availability of endothelial von Willebrand factor and platelet function in diabetic patients infused with a vasopressin analogue.
    Diabetologia, 1982, Volume: 23, Issue:5

    Topics: Adenosine Diphosphate; Adult; Antigens; Arginine Vasopressin; Aspirin; Blood Coagulation Factors; De

1982
Clinical trials and statistical verdicts: probable grounds for appeal.
    Annals of internal medicine, 1983, Volume: 98, Issue:3

    Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Humans; Jurisprudence; Lung

1983
Platelet factor 4 levels in patients with coronary artery disease.
    The Journal of laboratory and clinical medicine, 1981, Volume: 97, Issue:3

    Topics: Acute Disease; Adult; Aged; Aspirin; Blood Coagulation Factors; Coronary Artery Bypass; Coronary Dis

1981
Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependent diabetes.
    Acta endocrinologica. Supplementum, 1980, Volume: 239

    Topics: Aspirin; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Humans; Insulin; Male

1980
Atherosclerosis in diabetes mellitus.
    Journal of chronic diseases, 1981, Volume: 34, Issue:1

    Topics: Arteriosclerosis; Aspirin; Blood Platelets; Diabetes Complications; Diabetes Mellitus; Epoprostenol;

1981
The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.
    Metabolism: clinical and experimental, 1981, Volume: 30, Issue:3

    Topics: Adult; Aged; Arginine; Aspirin; Blood Glucose; C-Peptide; Diabetes Mellitus; Female; Glucagon; Gluco

1981
A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics.
    Metabolism: clinical and experimental, 1981, Volume: 30, Issue:11

    Topics: Adult; Aged; Arginine; Aspirin; Blood Glucose; Diabetes Mellitus; Glucose; Humans; Insulin; Insulin

1981
Effect of acetylsalicylic acid on blood glucose and glucose regulatory hormones in mild diabetes.
    Prostaglandins, leukotrienes, and medicine, 1982, Volume: 8, Issue:1

    Topics: Adult; Aged; Aspirin; Blood Glucose; Diabetes Mellitus; Female; Gastric Inhibitory Polypeptide; Gast

1982
Secondary prevention in myocardial infarction survivors.
    Circulation, 1982, Volume: 65, Issue:1

    Topics: Anticoagulants; Aspirin; Diabetes Mellitus; Diet, Reducing; Humans; Hypertension; Lipids; Myocardial

1982
[Several methods of treatment of diabetes mellitus and its complications].
    Terapevticheskii arkhiv, 1982, Volume: 54, Issue:3

    Topics: Acid-Base Equilibrium; Adult; Aspirin; Blood Viscosity; Diabetes Mellitus; Diabetic Angiopathies; Di

1982
Effect of aspirin on platelet aggregation in diabetes mellitus.
    Diabetologia, 1982, Volume: 23, Issue:2

    Topics: Arachidonic Acids; Aspirin; Collagen; Diabetes Mellitus; Diabetic Retinopathy; Humans; Middle Aged;

1982
[Diamicron and micristin in the complex treatment of diabetes mellitus].
    Terapevticheskii arkhiv, 1982, Volume: 54, Issue:10

    Topics: Adult; Aspirin; Cellulose; Crystallization; Diabetes Mellitus; Drug Therapy, Combination; Gliclazide

1982
Effects of acetylsalicylic acid on plasma glucose, free fatty acid, betahydroxybutyrate, glucagon and C-peptide responses to salbutamol in insulin-dependent diabetic subjects.
    Acta diabetologica latina, 1981, Volume: 18, Issue:1

    Topics: Adult; Albuterol; Aspirin; Blood Glucose; C-Peptide; Diabetes Mellitus; Fatty Acids, Nonesterified;

1981
Platelet life-span in diabetics with and without retinopathy.
    Thrombosis research, 1981, Mar-15, Volume: 21, Issue:6

    Topics: Adult; Aspirin; Blood Glucose; Blood Platelets; Cell Survival; Diabetes Complications; Diabetes Mell

1981
Which diabetic patients should be taking aspirin?
    BMJ (Clinical research ed.), 1995, Sep-09, Volume: 311, Issue:7006

    Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors; Risk Fac

1995
Chromatographic evaluation of minor hemoglobins: clinical significance of hemoglobin A1d, comparison with hemoglobin A1c, and possible interferences.
    Clinical chemistry, 1995, Volume: 41, Issue:5

    Topics: Aspirin; Chromatography, Affinity; Chromatography, High Pressure Liquid; Diabetes Mellitus; Erythroc

1995
Glycation-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperone, alpha-crystallin.
    Biochimica et biophysica acta, 1996, Apr-12, Volume: 1315, Issue:3

    Topics: Animals; Aspirin; Carbohydrates; Cataract; Crystallins; Diabetes Complications; Diabetes Mellitus; G

1996
Presence and treatment of vascular risk factors in patients with vascular cognitive impairment.
    Archives of neurology, 1997, Volume: 54, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspirin; Cognition Disorders; Dementia; Diabetes Complic

1997
Secular trends in stroke mortality in African Americans: the role of urbanization, diabetes and obesity.
    Neuroepidemiology, 1997, Volume: 16, Issue:4

    Topics: Adult; Aged; Aspirin; Black People; Cerebrovascular Disorders; Diabetes Mellitus; Female; Fibrinolyt

1997
[Should one prescribe aspirin for all diabetics?].
    Diabetes & metabolism, 1997, Volume: 23, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega

1997
Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Austral

1998
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Thrombosis and haemostasis, 1998, Volume: 80, Issue:6

    Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Aspirin; Co

1998
Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
    Journal of internal medicine, 1999, Volume: 245, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose;

1999
Aspirin and risk of hemorrhagic stroke.
    JAMA, 1999, Aug-25, Volume: 282, Issue:8

    Topics: Aspirin; Cerebral Hemorrhage; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Risk

1999
Meeting report of the ASPET-Ray Fuller Symposium: insulin resistance in diabetes and hypertension: syndrome X and beyond.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:1

    Topics: Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Endot

2000
Sex differences and similarities in the management and outcome of stroke patients.
    Stroke, 2000, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity;

2000
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human

2000
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
    Diabetes care, 2001, Volume: 24, Issue:2

    Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe

2001
Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?
    American heart journal, 2001, Volume: 142, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure

2001
Acute myocardial infarction in the young--The University of Michigan experience.
    American heart journal, 2002, Volume: 143, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Anticoagulants; Aspirin; Coronary Artery B

2002
Aspirin therapy in diabetes.
    Diabetes care, 2000, Volume: 23 Suppl 1

    Topics: Aspirin; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Humans; Platelet Aggre

2000
Aspirin use and counseling about aspirin among patients with diabetes.
    Diabetes care, 2002, Volume: 25, Issue:6

    Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Health Kno

2002
Methods for detection of hypersensitive platelets. Philadelphia, June 1977.
    Thrombosis and haemostasis, 1978, Aug-31, Volume: 40, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiovascular

1978
Classification of platelet aggregation patterns with two ADP solutions (the double-ADP method) and its clinical application to diabetes mellitus.
    Thrombosis research, 1977, Volume: 11, Issue:4

    Topics: Adenosine Diphosphate; Adult; Aged; Aging; Aspirin; Blood Glucose; Cholesterol; Diabetes Mellitus; D

1977
Diclofenac sodium (Voltarol): drug interactions and special studies.
    Rheumatology and rehabilitation, 1979, Volume: Suppl 2

    Topics: Adult; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Blood Coagulation Factors; Blood Glucose;

1979
Acetylsalicylic acid augments insulin and C-peptide responses to arginine in diabetes mellitus.
    Prostaglandins and medicine, 1979, Volume: 2, Issue:2

    Topics: Adult; Arginine; Aspirin; Blood Glucose; C-Peptide; Diabetes Mellitus; Female; Humans; Insulin; Insu

1979
Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon.
    The Journal of clinical investigation, 1979, Volume: 63, Issue:3

    Topics: Adult; Aged; Aspirin; Chromatography, DEAE-Cellulose; Chromatography, Gel; Diabetes Mellitus; Dipyri

1979
Platelet survival in diabetes mellitus using an aspirin-labelling technique.
    Thrombosis research, 1979, Volume: 15, Issue:5-6

    Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelets; Cell Survival; Diabetes Mellitus; Female; Humans;

1979
Dietary prevention of atherosclerosis: new aspects.
    Comprehensive therapy, 1979, Volume: 5, Issue:12

    Topics: Animals; Arteriosclerosis; Aspirin; Cholesterol, Dietary; Diabetes Mellitus; Diet; Heart; Hypertensi

1979
[The electrophoretic mobility of platelets. Short review of the literature and contribution with personal experience (author's transl)].
    Sangre, 1978, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aspirin; Blood Coagulation; Blood Platelets; Contraceptives, Oral; Diabetes Melli

1978
[Which anti-inflammatory and which analgesic agents should one select for diabetics?].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1978

    Topics: Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Diabetes Complications; Diabet

1978
[Significance of two concentrations of adenosine diphosphate inducing platelet aggregation in patients with diabetes mellitus (author's transl)].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1978, Volume: 15, Issue:6

    Topics: Adenosine Diphosphate; Adult; Aged; Aging; Aspirin; Diabetes Mellitus; Diabetic Retinopathy; Female;

1978
Altered platelet function in diabetes mellitus.
    Diabetes, 1976, Volume: 25, Issue:2 SUPPL

    Topics: Adenosine Diphosphate; Adult; Arachidonic Acids; Aspirin; Blood Platelets; Collagen; Cyclooxygenase

1976
Induced bleeding changes with aspirin in various tolerant and intolerant patient groups.
    Annals of allergy, 1975, Volume: 34, Issue:5

    Topics: Aspirin; Blood Coagulation Tests; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Diabetes Melli

1975
Increased platelet aggregation in early diabetus mellitus.
    Annals of internal medicine, 1975, Volume: 82, Issue:6

    Topics: Adenosine Diphosphate; Administration, Oral; Aspirin; Collagen; Diabetes Mellitus; Diabetic Angiopat

1975
Diabetes mellitus and insulin in an aspirin sensitive asthmatic.
    Annals of allergy, 1976, Volume: 36, Issue:3

    Topics: Aspirin; Asthma; Azo Compounds; Benzenesulfonates; Coloring Agents; Diabetes Complications; Diabetes

1976
[Cardiovascular risk factors and restenosis after PTCA].
    Zeitschrift fur Kardiologie, 1992, Volume: 81, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro

1992
Ischemic stroke. How to keep the first one from happening.
    Postgraduate medicine, 1991, Volume: 90, Issue:8

    Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; I

1991
Non-enzymatic glycosylation of keratin from the stratum corneum of the diabetic foot.
    The British journal of dermatology, 1985, Volume: 112, Issue:5

    Topics: Adult; Aged; Aspirin; Diabetes Mellitus; Epidermis; Foot; Glucose; Glycated Hemoglobin; Humans; In V

1985
[Determination of human sensitivity to the antiaggregation action of acetylsalicylic acid].
    Laboratornoe delo, 1986, Issue:4

    Topics: Arteriosclerosis; Aspirin; Diabetes Mellitus; Humans; Methods; Myocardial Infarction; Platelet Aggre

1986
Blood lipid peroxides in TIA: relation to platelet function and metabolic profile.
    Acta neurologica Scandinavica, 1989, Volume: 80, Issue:4

    Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Glucose; Blood Platelets; Coronary Dise

1989
In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin.
    Circulation, 1989, Volume: 79, Issue:1

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Bleeding Time; Diabetes Mellitus; Dose-Response Relati

1989
[Study of plasma beta thromboglobulin level induced by heparin in diabetic patients].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1988, Volume: 25, Issue:5

    Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Diabetes Mellitus; Diabetic Angiopathies; Female; Hepari

1988
Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    The Journal of laboratory and clinical medicine, 1986, Volume: 107, Issue:2

    Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Colla

1986
Trial of repeated low-dose aspirin in diabetic angiopathy.
    Blood, 1986, Volume: 68, Issue:4

    Topics: Adenosine Triphosphate; Adult; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Collag

1986
Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus.
    Thrombosis research, 1987, Aug-15, Volume: 47, Issue:4

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Arteriosclerosis; Aspirin; Diabetes Mellitus; Epoprostenol; Fem

1987
[Acylpyrin and glucose homeostasis in diabetes mellitus].
    Casopis lekaru ceskych, 1988, Jan-29, Volume: 127, Issue:5

    Topics: Adult; Aged; Aspirin; Diabetes Mellitus; Glucose; Homeostasis; Humans; Middle Aged; Receptor, Insuli

1988
[Effect of acetylsalicylic acid on thrombocyte function in patients with diabetes mellitus (review of the literature)].
    Vrachebnoe delo, 1987, Issue:1

    Topics: Aspirin; Blood Platelets; Diabetes Mellitus; Diabetic Angiopathies; Humans

1987
Non-enzymatic acetylation of proteins by aspirin as protection against the secondary complications of diabetes mellitus.
    Acta physiologica et pharmacologica latinoamericana : organo de la Asociacion Latinoamericana de Ciencias Fisiologicas y de la Asociacion Latinoamericana de Farmacologia, 1986, Volume: 36, Issue:3

    Topics: Acetylation; Aspirin; Diabetes Complications; Diabetes Mellitus; Glycosylation; Humans; In Vitro Tec

1986
Increased thromboxane B2 excretion in diabetes mellitus.
    The Journal of laboratory and clinical medicine, 1987, Volume: 109, Issue:6

    Topics: Adult; Aspirin; Blood Platelets; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Kidn

1987
The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid.
    Atherosclerosis, 1985, Volume: 55, Issue:1

    Topics: Adult; Aged; Arteriosclerosis; Aspirin; Blood Viscosity; Diabetes Mellitus; Female; Fibrinogen; Huma

1985
[Arachidonic acids].
    Rinsho byori. The Japanese journal of clinical pathology, 1985, Volume: Spec No 62

    Topics: Arachidonic Acids; Aspirin; Blood Platelets; Diabetes Mellitus; Humans; Methods; Myeloproliferative

1985
Treatment of atherosclerosis and thrombosis with aspirin.
    Lancet (London, England), 1972, Sep-09, Volume: 2, Issue:7776

    Topics: Adult; Age Factors; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Diabetes

1972
The effect of variation of lipolysis after nicotinic acid and acetylsalicylate on blood concentrations of 3-hydroxybutyrate and acetoacetate in starving subjects.
    Scandinavian journal of clinical and laboratory investigation, 1970, Volume: 25, Issue:4

    Topics: Acetoacetates; Adolescent; Adult; Aspirin; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterif

1970
The effect of some drugs on oxalic acid excretion in urine.
    Arzneimittel-Forschung, 1970, Volume: 20, Issue:2

    Topics: Ascorbic Acid; Aspirin; Asthma; Calcium; Citrates; Coronary Disease; Depression, Chemical; Diabetes

1970
Editorial: Aspirin and diabetic retinopathy.
    JAMA, 1974, Jun-03, Volume: 228, Issue:10

    Topics: Aspirin; Diabetes Mellitus; Diabetic Retinopathy; Humans; Platelet Adhesiveness; Time Factors

1974
Regular aspirin intake and acute myocardial infarction.
    British medical journal, 1974, Mar-09, Volume: 1, Issue:5905

    Topics: Adult; Age Factors; Aged; Arthritis; Aspirin; Diabetes Mellitus; Female; Humans; Hypertension; Male;

1974
Cystitis emphysematosa.
    Urology, 1974, Volume: 3, Issue:5

    Topics: Adult; Aspirin; Cephalexin; Cystitis; Cystoscopy; Diabetes Complications; Diabetes Mellitus; Diet, D

1974
Increased platelet aggregation in diabetes mellitus.
    The Journal of laboratory and clinical medicine, 1972, Volume: 80, Issue:2

    Topics: Adenosine Diphosphate; Aspirin; Blood Chemical Analysis; Blood Proteins; Creatinine; Diabetes Mellit

1972
Inhibition of glucose oxidase paper tests by reducing metabolites.
    Diabetes, 1970, Volume: 19, Issue:5

    Topics: Adult; Alkaptonuria; Aspirin; Diabetes Complications; Diabetes Mellitus; Dihydroxyphenylalanine; Fal

1970
Studies on salicylates and complement in diabetes.
    Diabetes, 1966, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aspirin; Complement System Proteins; Diabetes Mellitus; Diabetic Retinopathy; Fem

1966